PI3k assays and probe compounds therein

WO2024220380A3PCT designated stage expired Publication Date: 2024-11-21TOTUS MEDICINES INC
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
PCT/US2024/024712
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-04-16
Filing Date
2024-04-16
Publication Date
2024-11-21

AI Technical Summary

Technical Problem

Current methods for screening covalent therapeutic conjugates for their binding to biological targets are inefficient, particularly in differentiating true covalent binders from false positives and face challenges with mass spectrometry approaches that are limited in sensitivity and reproducibility.

Method used

A high-throughput combinatorial approach that synthesizes therapeutic conjugates and uses probe compounds with biotin labels, detected by streptavidin, to quantify covalent binding in cells through Western blot and other methods, enabling precise tracking of covalent drug binding and occupancy of PI3K inhibitors.

Benefits of technology

This method allows for rapid screening of thousands of molecules with high sensitivity and reproducibility, accurately determining covalent binding and occupancy of PI3K inhibitors, facilitating the development of effective therapeutic compounds.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2024024712_21112024_PF_FP_ABST
    Figure US2024024712_21112024_PF_FP_ABST
Patent Text Reader

Abstract

This disclosure relates to PI3K assays with therapeutic conjugates and / or probe compounds that covalently bind to the biological target, PI3K, and the probe compounds described herein.
Need to check novelty before this filing date? Find Prior Art

Description

PI3K ASSAYS AND PROBE COMPOUNDS THEREIN CROSS REFERENCE TO RELATED APPLICATIONS

[0001] This application claims priority to U.S. Provisional Application No. 63 / 496,404, filed April 16, 2023, the contents of which are hereby incorporated by reference in their entities for all purposes. FIELD OF THE DISCLOSURE

[0002] This disclosure generally relates to the binding of PI3K inhibitors to PI3K and the methods with the use of probe compound disclosed herein and assessing the efficacy of a provided irreversible inhibitor and / or assessing the pharmacodynamics of a provided irreversible inhibitor to PI3K. BACKGROUND

[0003] Covalent inhibitors bind to a receptor in the same way as a classic inhibitor, but instead of disassociating, covalent inhibitors form a covalent, permanent, chemical bond to the receptor. Some examples of covalent inhibitors include penicillin, aspirin, clopidogrel, EGFR kinase inhibitor Afatinib used to treat lung cancer, and Bruton Tyrosine kinase inhibitor Ibrutinib used to treat B-cell malignancies. Furthermore, in the field of oncology, covalent inhibitors are effective against drug-resistant tumors, and in general display more potency at inhibiting tumor growth.

[0004] Recently, covalent inhibitors have attracted the attention of major pharmaceutical companies because the use of covalent inhibitors offers an increased potency and extended duration of action when compared to classic reversible inhibitors. Prolonged duration of action translates into lower dosage frequency, i.e., patients have to take fewer pills and take it less frequently.

[0005] There is a need to design and understand therapeutic compounds that can bind to a biological target covalently and to develop high throughput screening methods for the therapeutic compounds, and to be able to understand the binding characteristics and pharmacodynamics of said compounds. SUMMARY OF THE INVENTION

[0006] In some embodiments, the present disclosure provides a method for detecting and / or determining the amount of binding of a target PI3K inhibitor to PI3K. In a specific embodiment, the method may comprise incubating the target PI3K inhibitor with the PI3K, adding a probe compound to PI3K, and determining the amount of target modified by theprobe compound by detecting the probe. In a specific embodiment, the method determines the target occupancy of the target PI3K inhibitor to the kinase PI3K. In a specific embodiment, the kinase is the PI3K is PI3Kα. In another embodiment, the method determines the pharmacodynamics of the target PI3K inhibitor and / or the probe compound.

[0007] In a specific embodiment, the pharmacodynamics of the target PI3K irreversible inhibitor is determined by incubating the target PI3K irreversible inhibitor with the PI3K, adding the probe compound to PI3K, and determining the amount of target modified by the probe compound or measuring the activity of the detectable moiety of the probe compound by detecting the probe compound at different time points following the administration of the target PI3K inhibitor.

[0008] In another embodiment, the step of incubating the target PI3K inhibitor with the PI3K includes providing a dose titration of the target PI3K inhibitor. This may include methods of applying the use of multiple cells or lysates in different wells (such as an ELISA well), cuvette, tube, or separate assay, for each concentration of the target PI3K inhibitor.

[0009] In a specific embodiment, the assay is performed in vitro or in vivo. In another embodiment, the method is presented within one or more cells or a lysate thereof.

[0010] In another specific embodiment, the cells are lysed during the assay. In one embodiment, the target PI3K inhibitor is added to the pre-lysed cells, the cells are then lysed, and the probe added to the lysed cells.

[0011] In a specific embodiment of the methods described herein, the one or more cells are peripheral blood mononuclear cells (PBMCs). In a specific embodiment, the PBMCs are B cells. In another embodiment, the one or more cells are breast cancer cells. In another specific embodiment, the breast cancer cells are T-47D cells. In another embodiment, methods are performed with the cell lysates of the cells described herein.

[0012] In a specific embodiment, the target PI3K inhibitor is an irreversible and / or a covalent inhibitor of PI3K. In a specific embodiment, the target PI3K inhibitor is selected from the group consisting of Compound 1-101 to Compound 1-172 disclosed herein. In another specific embodiment, the target PI3K inhibitor is Compound 1-102. In another specific embodiment, the probe compound is covalently bound to a linker, and the linker (L) is bound to a label (Z) used for detection. In a specific embodiment, the probe compound is a compound from Formula I. In another embodiment, the compound of Formula I is covalently bound to a linker (L), a label (Z), or a linker that is then also bound to a label (Z). In a specific embodiment, the label Z is biotin or a modified biotin.

[0013] In another embodiment of the methods herein, the probe compound is detected byone of more of the group consisting of Western blot, ELISA, flow cytometry, and mass spectrometry, including LC-MS, and LC-MS-MS.

[0014] In another specific embodiment, the probe compound is detected by the use of binding to avidin, streptavidin, neutravidin, or captavidin.

[0015] In a specific embodiment, the methods may include detecting and / or determining the amount of binding of a target PI3K inhibitor to PI3K in cells or a cell lysate thereof, comprising incubating the target PI3K inhibitor with the PI3K; adding a biotinylated probe compound to PI3K; adding streptavidin or avidin to specifically bind to the biotin, thereby creating an increase in mass to the PI3K bound to the probe, but not to the PI3K bound to the target PI3K inhibitor; running gel electrophoresis and detecting the probe with Western blot of the incubated cell lysate utilizing an anti-PI3K antibody, and determining the amount of target modified by the probe compound by detecting the probe, such as by determining the bands or peaks.

[0016] In a specific embodiment, the methods may include detecting and / or determining the amount of binding or occupancy of a target PI3K inhibitor to PI3K in cells, comprising incubating the target PI3K inhibitor with the PI3K in pre-lysed cells; then lysing the cells before addition of a biotinylated probe compound; adding a biotinylated probe compound to PI3K; adding streptavidin or avidin to specifically bind to the biotin, thereby creating an increase in mass to the PI3K bound to the probe, but not to the PI3K bound to the target PI3K inhibitor; running gel electrophoresis and detecting the probe with Western blot of the incubated cell lysate utilizing an anti-PI3K antibody, and determining the amount of target occupied or modified by the probe compound by detecting the probe.

[0017] In another specific embodiment, the pharmacodynamics of the target PI3K irreversible inhibitor is determined by incubating the target PI3K irreversible inhibitor with the PI3K, adding a probe compound to PI3K, and determining the amount of target modified by the probe compound or measuring the activity of the detectable moiety of the probe compound by detecting the probe compound at different time points following the administration of the target PI3K inhibitor. In a specific embodiment, the probe is biotinylated. In a specific embodiment, the biotinylated is assisted with detection by adding streptavidin or avidin to specifically bind to the biotin, thereby creating an increase in mass to the PI3K bound to the probe (unoccupied PI3K), but not to the PI3K bound to the target PI3K inhibitor (occupied PI3K).

[0018] In another embodiment, the assay can be used to determine the appropriate dose of a target PI3K inhibitor to a patient in a clinical setting. Specifically, by determining theoccupancy of the target PI3K inhibitor to the PI3K target in pre-lysed cells, such as the use of whole blood, or PBMCs from whole blood, an approximate maximum clinical dose can be determined for administering to a subject by correlating concentration of the target PI3K inhibitor administered to the whole blood or cell, and occupancy rate of PI3K. For example, in a clinical setting for drugs with adverse side effects, it would be preferrable to minimize the dose and not dose higher if the occupancy of a known concentration of PI3K is already at 100%, close to 100%, or if the occupancy plateaus at a certain concentration or dose used during the assay of the target PI3K inhibitor. In a specific embodiment, the maximum tolerated dose in a clinical setting can be estimated or determined by identifying the occupancy of the target PI3K inhibitor in the assays described herein.

[0019] In another embodiment, the methods and assays described herein can be utilized to determine the stability and / or degradation of a target PI3K inhibitor bound to PI3K. In a specific embodiment, a target PI3K inhibitor is added to a cell line of interest comprising PI3K. The cells comprising the target PI3K inhibitor may then be washed, and then monitored at different washout times to observe if the target PI3K inhibitor covalently bound to PI3K is stable. In a specific embodiment, the washout time can be for about 1 hr, 2, hrs, 3 hrs, 4 hrs, 5 hrs, 6 hrs, 7hrs, 8 hrs, 9 hrs, 10 hrs, 11 hrs, 12 hrs, 14 hrs, 16 hrs, 18 hrs 20 hrs, 24 hrs, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, or anytime necessary to monitor degradation of the target PI3K inhibitor covalently bound to PI3K. After the washout time, the cells are lysed and the probe compound is added to the lysed cells. Streptavidin can then be added to increase mass, followed by gel electrophoresis and Western blot. Degradation of stability of the occupied PI3K can then be determined by observing occupancy at the different lengths of time post-wash.

[0020] The kinase may be PI3-kinase (PI3K). The present invention further comprises probe compounds for the PI3K assay. The probe compounds may have a structure of Formula I: (FCB)a-(L)b-(CLM)c, wherein a and c are, independently, integers between 1 and 5, b is an integer between 0 and 5, and wherein the FCB moiety comprises a PI3K inhibitor, or a fragment, analog or derivative thereof. In some embodiments, the FCB may comprise. The probe compound may comprise a structure selected from the group consisting of Compound 1-101 to Compound 1-172 disclosed herein.

[0021] In some embodiments, the probe compound may have a structure of Formula II: (Formula II) or a pharmaceutically acceptable salt thereof,wherein L is selected from the group consisting ofwherein either end can be connected to CLM; R1 is selected from the group consisting ofThe probe compound may be selected from the group consisting of compounds 1-101, 1-102, 1-103, 1-104, 1-105, 1-106, 1-107, 1-108, 1-109, 1- 110, 1-111, 1-112, 1-113, 1-114, 1-115, 1-116, 1-117, 1-118, 1-119, 1-120, 1-121, 1-122, 1-123, 1-124, 1-125, 1-126, 1-127, 1-128, 1-129, 1-130, 1-137, 1-138, 1-145, 1-146, 1-153, 1- 154, 1-161, 1-162, 1-169, 1-170, 1-171 and 1-172.

[0022] In some embodiments, the probe compound may have a structure of Formula III:Formula III, or a pharmaceutically acceptable salt thereof, wherein L isR2 is selected from the group consisting of; and CLM is selected from the group consisting of , ,The probe compound may be selected from the group consisting of compounds 1-131, 1-132, 1-133, 1-134, 1-135, 1- 136, 1-139, 1-140, 1-141, 1-142, 1-143, 1-144, 1-147, 1-148, 1-149, 1-150, 1-151, 1-152, 1- 155, 1-156, 1-157, 1-158, 1-159, 1-160, 1-163, 1-164, 1-165, 1-166, 1-167 and 1-168.

[0023] In some embodiments, the probe compound may comprise a structure selected from Compound 1-101 to Compound 1-172, or a pharmaceutical acceptable salt thereof. In some embodiments, the probe compound may comprise a structure selected from Compound 1-1 to Compound 1-11, or a pharmaceutical acceptable salt thereof. In a specific embodiment, the probe compounds may be further covalently bound to a linker and / or a label Z.

[0024] In a specific embodiment, the target PI3K inhibitor is compound 1-102 and the probe compound is compound A with a biotin label. In another embodiment, the presentinvention includes an assay that determines the occupancy of compound 1-102 to PI3Kα with the use of compound A as the probe compound. In a specific embodiment, a clinical dose for a patient such as a human can be determined or estimated by determining the occupancy of the compound 1-102 to PI3Kα. BRIEF DESCRIPTION OF THE DRAWINGS

[0025] Figure 1 depicts the use of various biotin probe compounds A-E and C-1 for use in the methods herein for binding to PI3Kα.

[0026] Figure 2 depicts a dose dependent correlation of compound 1-102 occupancy of PI3Kα and pathway inhibition in T-47D cells.

[0027] Figure 3 depicts a titration of compound 1-102 occupancy of PI3Kα in Human PBMCs in two different donor samples.

[0028] Figure 4 depicts a titration of compound 1-102 occupancy of PI3Kα in PBMCs and T-47D cell lysates.

[0029] Figure 5 depicts the % PI3Kα bound in PBMCs by concentration of compound 1- 102.

[0030] Figure 6 depicts the % PI3Kα bound in PBMCs isolated from whole blood by concentration of compound 1-102.

[0031] Figure 7 shows the degradation / stability of compound 1-102 bound to PI3Kα in both AGC and T-47D cells.

[0032] Figure 8 shows the correlation of increased % PI3Kα bound to AKT S473 phosphorylation.

[0033] Figure 9 shows the correlation of increased % PI3Kα bound to AKT S473 phosphorylation in both T-47D cell cultures and T84 cell cultures. DETAILED DESCRIPTION I. Definitions

[0034] As used herein, the term “assay” refers to the sequence of activities associated with a reported result, which can include, but is not limited to: cell seeding, preparation of the test material, infection, lysis, analysis, and calculation of results.

[0035] The term “biological target”, as used herein, refers to any target to which an FCB binds non-covalently to product a therapeutic effect. A CLM binds to the biological target covalently. In some embodiments, the biological target is a protein. Non-limiting examples of biological targets include kinase such as, but not limited to phosphoinositide 3-kinases (PI3Ks) and pseudokinase.

[0036] The term “FCB” as used herein, refers to a therapeutic modality that can be a known drug, a diagnostic compound, a drug candidate and a functional fragment and / or combination of any of the forgoing. The FCB encompasses free acid and free base forms; optical and tautomeric isomers; isotopes including radioisotopes and pharmaceutically acceptable salts of the drug, prodrug or fragment thereof. The FCBs may be small molecules, proteins, peptides, lipids, carbohydrates, sugars, nucleic acids, or combination thereof. In some embodiments, the FCBs are nucleic acids including, but is not limited to DNA or RNA. The FCB may be a therapeutic agent such as, but not limited to, anticancer agents, anti- neurodegenerative agents, autoimmune drugs and anti-aging agents. The FCB may bind to a biological target non-covalently. In some embodiments, the FCB may be a functional fragment of a drug. The term “functional fragment” as used herein, refers to a part of a drug or derivative or analog thereof that is capable of inducing a desired effect of the drug. In some embodiments, the FCB may comprise an alkyne functional group. In some embodiments, the FCB may not comprise an alkyne functional group.

[0037] As used herein, the term "peptide", "polypeptide", "protein" refers to a polymer composed of amino acid monomers linked by an amide bond. Amino acids may be D- or L- optical isomer. Peptides may be formed by condensation or coupling reaction with the amino group of one α- carbon carboxyl group and another amino acid. Peptides may be non-linear branched peptides or cyclic peptides. Furthermore, the peptide may be optionally modified or protected with divergent functional group or a protecting group including amino and / or carboxy termini.

[0038] Amino acid residues of the peptide are abbreviated as follows. Phenylalanine is Phe or F, leucine is Leu or L, isoleucine is Ile or I, methionine is Met or M, valine is Val or V, serine is Ser or S, proline is Pro or P, threonine is Thr or T, alanine is Ala or a, tyrosine is Tyr or Y, histidine is His or H, glutamine is Gln or Q, asparagine Asn or is N, lysine is Lys or K, aspartic acid is Asp or D, glutamic acid is Glu or E, cysteine is Cys or C, tryptophan is Trp or W, arginine is Arg or R , and glycine is Gly or G.

[0039] The term “CLM” as used herein, refers to any covalent binding modality that is capable of forming a covalent bond with the biological target. The CLM may be linked to an FCB by a bond or by a linker. The CLM may comprise one or more chemical moieties which can form a covalent bond with the biological target. The chemical moieties may be an electrophilic or nucleophilic group.

[0040] The term "linker" as used herein, refers to an organic moiety that connects two parts of a compound. The linker can be external linker or internal linker. The external linkercan connect FCB and CLM moieties or the probe compound to a label (Z). The linker can be cleavable or non-cleavable.

[0041] The term "alkyl" refers to the radical of saturated aliphatic groups, including straight-chain alkyl groups, branched-chain alkyl groups, cycloalkyl (alicyclic) groups, alkyl- substituted cycloalkyl groups, and cycloalkyl-substituted alkyl groups.

[0042] In some embodiments, a straight chain or branched chain alkyl has 30 or fewer carbon atoms in its backbone (e.g., C1-C30for straight chains, C3-C30for branched chains), 20 or fewer, 12 or fewer, or 7 or fewer. Likewise, in some embodiments cycloalkyls have from 3-10 carbon atoms in their ring structure, e.g. have 5, 6 or 7 carbons in the ring structure. The term "alkyl" (or "lower alkyl") as used throughout the specification, examples, and claims is intended to include both "unsubstituted alkyls" and "substituted alkyls", the latter of which refers to alkyl moieties having one or more substituents replacing a hydrogen on one or more carbons of the hydrocarbon backbone. Such substituents include, but are not limited to, halogen, hydroxyl, carbonyl (such as a carboxyl, alkoxycarbonyl, formyl, or an acyl), thiocarbonyl (such as a thioester, a thioacetate, or a thioformate), alkoxyl, phosphoryl, phosphate, phosphonate, a phosphinate, amino, amido, amidine, imine, cyano, nitro, azido, sulfhydryl, alkylthio, sulfate, sulfonate, sulfamoyl, sulfonamido, sulfonyl, heterocyclyl, aralkyl, or an aromatic or heteroaromatic moiety.

[0043] Unless the number of carbons is otherwise specified, "lower alkyl" as used herein means an alkyl group, as defined above, but having from one to ten carbons, or from one to six carbon atoms in its backbone structure. Likewise, "lower alkenyl" and "lower alkynyl" have similar chain lengths. Throughout the application, preferred alkyl groups are lower alkyls. In some embodiments, a substituent designated herein as alkyl is a lower alkyl.

[0044] It will be understood by those skilled in the art that the moieties substituted on the hydrocarbon chain can themselves be substituted, if appropriate. For instance, the substituents of a substituted alkyl may include halogen, hydroxy, nitro, thiols, amino, azido, imino, amido, phosphoryl (including phosphonate and phosphinate), sulfonyl (including sulfate, sulfonamido, sulfamoyl and sulfonate), and silyl groups, as well as ethers, alkylthios, carbonyls (including ketones, aldehydes, carboxylates, and esters), -CF3, -CN and the like. Cycloalkyls can be substituted in the same manner.

[0045] The term “heteroalkyl”, as used herein, refers to straight or branched chain, or cyclic carbon-containing radicals, or combinations thereof, containing at least one heteroatom. Suitable heteroatoms include, but are not limited to, O, N, Si, P, Se, B, and S, wherein the phosphorous and sulfur atoms are optionally oxidized, and the nitrogenheteroatom is optionally quaternized. Heteroalkyls can be substituted as defined above for alkyl groups.

[0046] The term "alkylthio" refers to an alkyl group, as defined above, having a sulfur radical attached thereto. In some embodiments, the "alkylthio" moiety is represented by one of -S-alkyl, -S-alkenyl, and -S-alkynyl. Representative alkylthio groups include methylthio, and ethylthio. The term “alkylthio” also encompasses cycloalkyl groups, alkene and cycloalkene groups, and alkyne groups. “Arylthio” refers to aryl or heteroaryl groups. Alkylthio groups can be substituted as defined above for alkyl groups.

[0047] The terms "alkenyl" and "alkynyl", refer to unsaturated aliphatic groups analogous in length and possible substitution to the alkyls described above, but that contain at least one double or triple bond respectively.

[0048] The terms "alkoxyl" or "alkoxy" as used herein refers to an alkyl group, as defined above, having an oxygen radical attached thereto. Representative alkoxyl groups include methoxy, ethoxy, propyloxy, and tert-butoxy. An "ether" is two hydrocarbons covalently linked by an oxygen. Accordingly, the substituent of an alkyl that renders that alkyl an ether is or resembles an alkoxyl, such as can be represented by one of -O-alkyl, -O-alkenyl, and - O-alkynyl. Aroxy can be represented by –O-aryl or O-heteroaryl, wherein aryl and heteroaryl are as defined below. The alkoxy and aroxy groups can be substituted as described above for alkyl.

[0049] The terms "amine" and "amino" are art-recognized and refer to both unsubstituted and substituted amines, e.g., a moiety that can be represented by the general formula:wherein R9, R10, and R'10each independently represent a hydrogen, an alkyl, an alkenyl, -(CH2)m-R8or R9and R10taken together with the N atom to which they are attached complete a heterocycle having from 4 to 8 atoms in the ring structure; R8 represents an aryl, a cycloalkyl, a cycloalkenyl, a heterocycle or a polycycle; and m is zero or an integer in the range of 1 to 8. In some embodiments, only one of R9or R10can be a carbonyl, e.g., R9, R10and the nitrogen together do not form an imide. In still other embodiments, the term “amine” does not encompass amides, e.g., wherein one of R9and R10represents a carbonyl. In additional embodiments, R9and R10(and optionally R’10) each independently represent a hydrogen, an alkyl or cycloalkyl, an alkenyl or cycloalkenyl, or alkynyl. Thus, the term "alkylamine" as used herein means an amine group, as defined above,having a substituted (as described above for alkyl) or unsubstituted alkyl attached thereto, i.e., at least one of R9and R10is an alkyl group.

[0050] The term "amido" is art-recognized as an amino-substituted carbonyl and includes a moiety that can be represented by the general formula:, wherein R9and R10are as defined above.

[0051] “Aryl”, as used herein, refers to C5-C10-membered aromatic, heterocyclic, fused aromatic, fused heterocyclic, biaromatic, or bihetereocyclic ring systems. Broadly defined, “aryl”, as used herein, includes 5-, 6-, 7-, 8-, 9-, and 10-membered single-ring aromatic groups that may include from zero to four heteroatoms, for example, benzene, pyrrole, furan, thiophene, imidazole, oxazole, thiazole, triazole, pyrazole, pyridine, pyrazine, pyridazine and pyrimidine, and the like. Those aryl groups having heteroatoms in the ring structure may also be referred to as “aryl heterocycles” or “heteroaromatics”. The aromatic ring can be substituted at one or more ring positions with one or more substituents including, but not limited to, halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, alkoxyl, amino (or quaternized amino), nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, sulfonamido, ketone, aldehyde, ester, heterocyclyl, aromatic or heteroaromatic moieties, -CF3, -CN; and combinations thereof.

[0052] The term “aryl” also includes polycyclic ring systems having two or more cyclic rings in which two or more carbons are common to two adjoining rings (i.e., “fused rings”) wherein at least one of the rings is aromatic, e.g., the other cyclic ring or rings can be cycloalkyls, cycloalkenyls, cycloalkynyls, aryls and / or heterocycles. Examples of heterocyclic rings include, but are not limited to, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzoxazolinyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazolinyl, carbazolyl, 4aH carbazolyl, carbolinyl, chromanyl, chromenyl, cinnolinyl, decahydroquinolinyl, 2H,6H- 1,5,2-dithiazinyl, dihydrofuro[2,3 b]tetrahydrofuran, furanyl, furazanyl, imidazolidinyl, imidazolinyl, imidazolyl, 1H-indazolyl, indolenyl, indolinyl, indolizinyl, indolyl, 3H-indolyl, isatinoyl, isobenzofuranyl, isochromanyl, isoindazolyl, isoindolinyl, isoindolyl, isoquinolinyl, isothiazolyl, isoxazolyl, methylenedioxyphenyl, morpholinyl, naphthyridinyl, octahydroisoquinolinyl, oxadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, oxazolidinyl, oxazolyl, oxindolyl, pyrimidinyl, phenanthridinyl,phenanthrolinyl, phenazinyl, phenothiazinyl, phenoxathinyl, phenoxazinyl, phthalazinyl, piperazinyl, piperidinyl, piperidonyl, 4-piperidonyl, piperonyl, pteridinyl, purinyl, pyranyl, pyrazinyl, pyrazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pyridooxazole, pyridoimidazole, pyridothiazole, pyridinyl, pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolinyl, 2H-pyrrolyl, pyrrolyl, quinazolinyl, quinolinyl, 4H-quinolizinyl, quinoxalinyl, quinuclidinyl, tetrahydrofuranyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, tetrazolyl, 6H-1,2,5-thiadiazinyl, 1,2,3- thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, thianthrenyl, thiazolyl, thienyl, thienothiazolyl, thienooxazolyl, thienoimidazolyl, thiophenyl and xanthenyl. One or more of the rings can be substituted as defined above for “aryl”.

[0053] The term "aralkyl", as used herein, refers to an alkyl group substituted with an aryl group (e.g., an aromatic or heteroaromatic group).

[0054] The term "carbocycle", as used herein, refers to an aromatic or non-aromatic ring in which each atom of the ring is carbon.

[0055] “Heterocycle” or “heterocyclic”, as used herein, refers to a cyclic radical attached via a ring carbon or nitrogen of a monocyclic or bicyclic ring containing 3-10 ring atoms, and preferably from 5-6 ring atoms, consisting of carbon and one to four heteroatoms each selected from the group consisting of non-peroxide oxygen, sulfur, and N(Y) wherein Y is absent or is H, O, (C1-C10) alkyl, phenyl or benzyl, and optionally containing 1-3 double bonds and optionally substituted with one or more substituents. Examples of heterocyclic ring include, but are not limited to, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzoxazolinyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazolinyl, carbazolyl, 4aH-carbazolyl, carbolinyl, chromanyl, chromenyl, cinnolinyl, decahydroquinolinyl, 21,5,2-dithiazinyl, dihydrofuro[2,3-b]tetrahydrofuran, furanyl, furazanyl, imidazolidinyl, imidazolinyl, imidazolyl, 1H-indazolyl, indolenyl, indolinyl, indolizinyl, indolyl, 3H-indolyl, isatinoyl, isobenzofuranyl, isochromanyl, isoindazolyl, isoindolinyl, isoindolyl, isoquinolinyl, isothiazolyl, isoxazolyl, methylenedioxyphenyl, morpholinyl, naphthyridinyl, octahydroisoquinolinyl, oxadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, oxazolidinyl, oxazolyl, oxepanyl, oxetanyl, oxindolyl, pyrimidinyl, phenanthridinyl, phenanthrolinyl, phenazinyl, phenothiazinyl, phenoxathinyl, phenoxazinyl, phthalazinyl, piperazinyl, piperidinyl, piperidonyl, 4-piperidonyl, piperonyl, pteridinyl, purinyl, pyranyl, pyrazinyl, pyrazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pyridooxazole, pyridoimidazole, pyridothiazole, pyridinyl, pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolinyl, 2H- pyrrolyl, pyrrolyl, quinazolinyl, quinolinyl, 4H-quinolizinyl, quinoxalinyl, quinuclidinyl,tetrahydrofuranyl, tetrahydroisoquinolinyl, tetrahydropyranyl, tetrahydroquinolinyl, tetrazolyl, 6H-1,2,5-thiadiazinyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, thianthrenyl, thiazolyl, thienyl, thienothiazolyl, thienooxazolyl, thienoimidazolyl, thiophenyl and xanthenyl. Heterocyclic groups can optionally be substituted with one or more substituents at one or more positions as defined above for alkyl and aryl, for example, halogen, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, amino, nitro, sulfhydryl, imino, amido, phosphate, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, ketone, aldehyde, ester, a heterocyclyl, an aromatic or heteroaromatic moiety, -CF3, and -CN.

[0056] The term "carbonyl" is art-recognized and includes such moieties as can be represented by the general formula:wherein X is a bond or represents an oxygen or a sulfur, and R11represents a hydrogen, an alkyl, a cycloalkyl, an alkenyl, an cycloalkenyl, or an alkynyl, R'11represents a hydrogen, an alkyl, a cycloalkyl, an alkenyl, an cycloalkenyl, or an alkynyl. Where X is an oxygen and R11or R'11is not hydrogen, the formula represents an "ester". Where X is an oxygen and R11is as defined above, the moiety is referred to herein as a carboxyl group, and particularly when R11is a hydrogen, the formula represents a "carboxylic acid". Where X is an oxygen and R'11is hydrogen, the formula represents a "formate". In general, where the oxygen atom of the above formula is replaced by sulfur, the formula represents a "thiocarbonyl" group. Where X is a sulfur and R11or R'11is not hydrogen, the formula represents a "thioester." Where X is a sulfur and R11is hydrogen, the formula represents a "thiocarboxylic acid." Where X is a sulfur and R'11is hydrogen, the formula represents a "thioformate." On the other hand, where X is a bond, and R11is not hydrogen, the above formula represents a "ketone" group. Where X is a bond, and R11is hydrogen, the above formula represents an "aldehyde" group.

[0057] The term “monoester” as used herein refers to an analog of a dicarboxylic acid wherein one of the carboxylic acids is functionalized as an ester and the other carboxylic acid is a free carboxylic acid or salt of a carboxylic acid. Examples of monoesters include, but are not limited to, to monoesters of succinic acid, glutaric acid, adipic acid, suberic acid, sebacic acid, azelaic acid, oxalic and maleic acid.

[0058] The term "heteroatom" as used herein means an atom of any element other than carbon or hydrogen. Examples of heteroatoms are boron, nitrogen, oxygen, phosphorus, sulfur and selenium. Other heteroatoms include silicon and arsenic.

[0059] As used herein, the term "nitro" means -NO2; the term "halogen" designates -F, - Cl, -Br or -I; the term "sulfhydryl" means -SH; the term "hydroxyl" means -OH; and the term "sulfonyl" means -SO2-.

[0060] The term “substituted” as used herein, refers to all permissible substituents of the compounds described herein. In the broadest sense, the permissible substituents include acyclic and cyclic, branched and unbranched, carbocyclic and heterocyclic, aromatic and nonaromatic substituents of organic compounds. Illustrative substituents include, but are not limited to, halogens, hydroxyl groups, or any other organic groupings containing any number of carbon atoms, preferably 1-14 carbon atoms, and optionally include one or more heteroatoms such as oxygen, sulfur, or nitrogen grouping in linear, branched, or cyclic structural formats. Representative substituents include alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, phenyl, substituted phenyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, halo, hydroxyl, alkoxy, substituted alkoxy, phenoxy, substituted phenoxy, aroxy, substituted aroxy, alkylthio, substituted alkylthio, phenylthio, substituted phenylthio, arylthio, substituted arylthio, cyano, isocyano, substituted isocyano, carbonyl, substituted carbonyl, carboxyl, substituted carboxyl, amino, substituted amino, amido, substituted amido, sulfonyl, substituted sulfonyl, sulfonic acid, phosphoryl, substituted phosphoryl, phosphonyl, substituted phosphonyl, polyaryl, substituted polyaryl, C3-C20cyclic, substituted C3-C20cyclic, heterocyclic, substituted heterocyclic, amino acid, peptide, and polypeptide groups.

[0061] Heteroatoms such as nitrogen may have hydrogen substituents and / or any permissible substituents of organic compounds described herein which satisfy the valences of the heteroatoms. It is understood that “substitution” or “substituted” includes the implicit proviso that such substitution is in accordance with permitted valence of the substituted atom and the substituent, and that the substitution results in a stable compound, i.e., a compound that does not spontaneously undergo transformation such as by rearrangement, cyclization, or elimination.

[0062] In a broad aspect, the permissible substituents include acyclic and cyclic, branched and unbranched, carbocyclic and heterocyclic, aromatic and nonaromatic substituents of organic compounds. Illustrative substituents include, for example, those described herein. The permissible substituents can be one or more and the same or different for appropriate organic compounds. The heteroatoms such as nitrogen may have hydrogen substituents and / or any permissible substituents of organic compounds described herein which satisfy the valencies of the heteroatoms.

[0063] In various embodiments, the substituent is selected from alkoxy, aryloxy, alkyl, alkenyl, alkynyl, amide, amino, aryl, arylalkyl, carbamate, carboxy, cyano, cycloalkyl, ester, ether, formyl, halogen, haloalkyl, heteroaryl, heterocyclyl, hydroxyl, ketone, nitro, phosphate, sulfide, sulfinyl, sulfonyl, sulfonic acid, sulfonamide, and thioketone, each of which optionally is substituted with one or more suitable substituents. In some embodiments, the substituent is selected from alkoxy, aryloxy, alkyl, alkenyl, alkynyl, amide, amino, aryl, arylalkyl, carbamate, carboxy, cycloalkyl, ester, ether, formyl, haloalkyl, heteroaryl, heterocyclyl, ketone, phosphate, sulfide, sulfinyl, sulfonyl, sulfonic acid, sulfonamide, and thioketone, wherein each of the alkoxy, aryloxy, alkyl, alkenyl, alkynyl, amide, amino, aryl, arylalkyl, carbamate, carboxy, cycloalkyl, ester, ether, formyl, haloalkyl, heteroaryl, heterocyclyl, ketone, phosphate, sulfide, sulfinyl, sulfonyl, sulfonic acid, sulfonamide, and thioketone can be further substituted with one or more suitable substituents.

[0064] Examples of substituents include, but are not limited to, halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, alkoxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, sulfonamido, ketone, aldehyde, thioketone, ester, heterocyclyl, –CN, aryl, aryloxy, perhaloalkoxy, aralkoxy, heteroaryl, heteroaryloxy, heteroarylalkyl, heteroaralkoxy, azido, alkylthio, oxo, acylalkyl, carboxy esters, carboxamido, acyloxy, aminoalkyl, alkylaminoaryl, alkylaryl, alkylaminoalkyl, alkoxyaryl, arylamino, aralkylamino, alkylsulfonyl, carboxamidoalkylaryl, carboxamidoaryl, hydroxyalkyl, haloalkyl, alkylaminoalkylcarboxy, aminocarboxamidoalkyl, cyano, alkoxyalkyl, perhaloalkyl, arylalkyloxyalkyl, and the like. In some embodiments, the substituent is selected from cyano, halogen, hydroxyl, and nitro.

[0065] The terms "polypeptide," "peptide" and "protein" generally refer to a polymer of amino acid residues. As used herein, the term also applies to amino acid polymers in which one or more amino acids are chemical analogs or modified derivatives of corresponding naturally occurring amino acids. The term "protein", as generally used herein, refers to a polymer of amino acids linked to each other by peptide bonds to form a polypeptide for which the chain length is sufficient to produce tertiary and / or quaternary structure. The term “protein” excludes small peptides by definition, the small peptides lacking the requisite higher-order structure necessary to be considered a protein.

[0066] A "functional fragment" of a protein, polypeptide or nucleic acid is a protein, polypeptide or nucleic acid whose sequence is not identical to the full-length protein, polypeptide or nucleic acid, yet retains at least one function as the full-length protein, polypeptide or nucleic acid. A functional fragment can possess more, fewer, or the samenumber of residues as the corresponding native molecule, and / or can contain one or more amino acid or nucleotide substitutions. Methods for determining the function of a nucleic acid (e.g., coding function, ability to hybridize to another nucleic acid) are well-known in the art. Similarly, methods for determining protein function are well-known. For example, the DNA binding function of a polypeptide can be determined, for example, by filter-binding, electrophoretic mobility shift, or immunoprecipitation assays. DNA cleavage can be assayed by gel electrophoresis. The ability of a protein to interact with another protein can be determined, for example, by co-immunoprecipitation, two-hybrid assays or complementation, e.g., genetic or biochemical. See, for example, Fields et al. (1989) Nature 340:245-246; U.S. Patent No.5,585,245 and PCT WO 98 / 44350.

[0067] The term “pharmaceutically acceptable counter ion” refers to a pharmaceutically acceptable anion or cation. In various embodiments, the pharmaceutically acceptable counter ion is a pharmaceutically acceptable ion. For example, the pharmaceutically acceptable counter ion is selected from citrate, malate, acetate, oxalate, chloride, bromide, iodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, isonicotinate, acetate, lactate, salicylate, tartrate, oleate, tannate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucaronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate and pamoate (i.e., 1,1'-methylene-bis- (2-hydroxy-3-naphthoate)). In some embodiments, the pharmaceutically acceptable counter ion is selected from chloride, bromide, iodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, citrate, malate, acetate, oxalate, acetate, and lactate. In particular embodiments, the pharmaceutically acceptable counter ion is selected from chloride, bromide, iodide, nitrate, sulfate, bisulfate, and phosphate.

[0068] The term “pharmaceutically acceptable salt(s)” refers to salts of acidic or basic groups that may be present in compounds used in the present compositions. Compounds included in the present compositions that are basic in nature are capable of forming a wide variety of salts with various inorganic and organic acids. The acids that may be used to prepare pharmaceutically acceptable acid addition salts of such basic compounds are those that form non-toxic acid addition salts, i.e., salts containing pharmacologically acceptable anions, including but not limited to sulfate, citrate, malate, acetate, oxalate, chloride, bromide, iodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, isonicotinate, acetate, lactate, salicylate, citrate, tartrate, oleate, tannate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucaronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate and pamoate (i.e., 1,1'-methylene-bis-(2-hydroxy-3-naphthoate)) salts. Compounds included in the present compositions that include an amino moiety may form pharmaceutically acceptable salts with various amino acids, in addition to the acids mentioned above. Compounds included in the present compositions, that are acidic in nature are capable of forming base salts with various pharmacologically acceptable cations. Examples of such salts include alkali metal or alkaline earth metal salts and, particularly, calcium, magnesium, sodium, lithium, zinc, potassium, and iron salts.

[0069] If the compounds described herein are obtained as an acid addition salt, the free base can be obtained by basifying a solution of the acid salt. Conversely, if the product is a free base, an addition salt, particularly a pharmaceutically acceptable addition salt, may be produced by dissolving the free base in a suitable organic solvent and treating the solution with an acid, in accordance with conventional procedures for preparing acid addition salts from base compounds. Those skilled in the art will recognize various synthetic methodologies that may be used to prepare non-toxic pharmaceutically acceptable addition salts.

[0070] A pharmaceutically acceptable salt can be derived from an acid selected from 1- hydroxy-2-naphthoic acid, 2,2-dichloroacetic acid, 2-hydroxyethanesulfonic acid, 2- oxoglutaric acid, 4-acetamidobenzoic acid, 4-aminosalicylic acid, acetic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, camphoric acid, camphor-10- sulfonic acid, capric acid (decanoic acid), caproic acid (hexanoic acid), caprylic acid (octanoic acid), carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane-1,2-disulfonic acid, ethanesulfonic acid, formic acid, fumaric acid, galactaric acid, gentisic acid, glucoheptonic acid, gluconic acid, glucuronic acid, glutamic acid, glutaric acid, glycerophosphoric acid, glycolic acid, hippuric acid, hydrobromic acid, hydrochloric acid, isethionic, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, mucic, naphthalene-1,5-disulfonic acid, naphthalene-2-sulfonic acid, nicotinic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, pamoic acid, pantothenic, phosphoric acid, proprionic acid, pyroglutamic acid, salicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, tartaric acid, thiocyanic acid, toluenesulfonic acid, trifluoroacetic, and undecylenic acid.

[0071] The term "detectable response" as used herein refers to an occurrence of, or a change in, a signal that is directly or indirectly detectable either by observation or by instrumentation. Typically, the detectable response is an occurrence of a signal wherein the fluorophore is inherently fluorescent and does not produce a change in signal upon binding toa metal ion or biological compound. Alternatively, the detectable response is an optical response resulting in a change in the wavelength distribution patterns or intensity of absorbance or fluorescence or a change in light scatter, fluorescence lifetime, fluorescence polarization, or a combination of the above parameters. Other detectable responses include, for example, chemiluminescence, phosphorescence, radiation from radioisotopes, magnetic attraction, and electron density. II. Assays, Kits and Methods of Use

[0072] The present disclosure provides a variety of assays and kits for conveniently and / or effectively carrying out methods of the present disclosure. Typically, kits will comprise sufficient amounts and / or numbers of components to allow a user to perform multiple treatments of a subject(s) and / or to perform multiple experiments.

[0073] The kit or assay may comprise packaging and instructions and / or a delivery agent to form a formulation composition. The delivery agent may comprise a saline, a buffered solution, or any delivery agent disclosed herein. The amount of each component may be varied to enable consistent, reproducible higher concentration saline or simple buffer formulations. The components may also be varied in order to increase the stability of a compound in the buffer solution over a period of time and / or under a variety of conditions.

[0074] The present disclosure provides for assays or kits which may incorporate one or more probe compounds and / or one or more target PI3K inhibitors of the present disclosure. These assays or kits may be used for individual, for example, diagnose a specific subject. In some embodiments, the subject has cancer. III. PI3K Assays

[0075] Covalent binding of a compound, such as a target PI3K inhibitor to a biological target, such as to PI3K , may be determined using various methods known in the art such as, but not limited to enzyme-linked immunosorbent assay (ELISA), gel assay, antibody array, western blot, affinity ELISA, ELISPOT, immunochemistry (e.g., IHC), in situ hybridization (ISH), flow cytometry, immunocytology, surface plasmon resonance analysis, kinetic exclusion assay, liquid chromatography-mass spectrometry (LCMS), tandem mass spectrometry (MS / MS), high-performance liquid chromatography (HPLC), BCA assay, immunoelectrophoresis, SDS-PAGE, protein immunoprecipitation, and / or PCR.

[0076] In some embodiments, the assay surfaces on the substrate are sterile and are suitable for culturing cells under conditions representative of the culture conditions during large-scale (e.g., industrial scale) production of the biological product. In some embodiments,the exterior of the substrate comprises wells, indentations, demarcations, or the like at positions corresponding to the assay surfaces. In some embodiments, the wells, indentations, demarcations, or the like retain fluid, such as cell culture media, over the assay surfaces.

[0077] In some embodiments, the substrate comprises a microarray plate, a biochip, or the like which allows for the high-throughput, automated testing of a range of test agents, conditions, and / or combinations thereof on the production of a biological product by cultured cells. For example, the substrate may comprise a 2-dimensional microarray plate or biochip having m columns and n rows of assay surfaces (e.g., residing within wells) which allow for the testing of m x n combinations of test agents and / or conditions (e.g., on a 24-, 96- or 384- well microarray plate). The microarray substrates are preferably designed such that all necessary positive and negative controls can be carried out in parallel with testing of the agents and / or conditions.

[0078] Generally, the syntheses of therapeutic conjugates or probe compounds that form a covalent bond with a biological target involve multiple synthetic and purification steps. When using such syntheses and purification steps, generating libraries of therapeutic conjugates for screening purposes or developing a structure-activity relationship (SAR) may be difficult. There remains a need for methods and systems that automatically generate therapeutic conjugate libraries by using methods of organic synthesis. To discover therapeutic conjugate drug leads, one has to screen a library of therapeutic conjugates against the protein receptor and identify those molecules that specifically bind to the receptor in a cellular setting, wherein the binding is covalent and irreversible. Identifying whether a therapeutic conjugate covalently binds a specific target in cells has been challenging to prove.

[0079] Current methods in the art for screening therapeutic conjugates for their covalent binding to the biological targets include tandem mass spectrometry approach. Tandem MS or MS / MS is a method to break down selected ions into fragment ions. Once samples are ionized to generate a mixture of ions, precursor ions of a specific mass-to-charge ratio (m / z) are selected (MS1) and then fragmented (MS2) to generate product ions for detection. Information about the chemical structure of the selected ion can be then determined from the fragments.

[0080] However, there are challenges associated with mass spectrometry approach. Mass spectrometry approaches are largely limited to fragment screens, not drug-like molecule screen. Mass spectrometry analysis of drug-like therapeutic conjugates would result in unresolved analysis as it will be difficult to identify several fragments. This approach involves multi-step process with long processing times and involves manual analysis. MS / MSwill defragment complex, larger molecules making it hard to interpret the resulting data as it requires manually combing through each peptide. Another disadvantage of using mass spectrometry approach is that the detection is proportional to ionization than abundance, making the technique weakly quantitative.

[0081] Accordingly, there are challenges associated with synthesis and screening of therapeutic conjugates. First, it is difficult to generate target covalent inhibitors which can access both cysteine and non-cysteine amino acids. It is also difficult to differentiate false positive covalent inhibitors from the real positives.

[0082] To address the foregoing issues, the inventors have combined combinatorial synthesis approaches with a reliable screening approach to identify potential therapeutic conjugates. The present disclosure provides a high throughput combinatorial approach to synthesize therapeutic conjugates; rapidly tracks covalent binding; analyzes large libraries for duration of action and directly quantifies covalent target binding in the cell.

[0083] Thousands of molecules can be screened per day with picomolar sensitivity as compared to tens of molecules with nanomolar sensitivity by using MS / MS method. The instant disclosure is amenable to any drug molecule and is not restrictive to fragments and gives quantitative results with 95-99% reproducibility.

[0084] In a specific embodiment, the kits or assays may be used to test specific or various cell lines. Examples of human cell lines useful in methods provided herein as target cells include, but are not limited to, 293T (embryonic kidney), 786-0 (renal), A498 (renal), A549 (alveolar basal epithelial), ACHN (renal), BT-549 (breast), BxPC-3 (pancreatic), CAKI-1 (renal), Capan-1 (pancreatic), CCRF-CEM (leukemia), COLO 205 (colon), DLD-1 (colon), DMS 114 (small cell lung), DU145 (prostate), EKVX (non-small cell lung), HCC-2998 (colon), HCT-15 (colon), HCT-116 (colon), HT29 (colon), HT-1080 (fibrosarcoma), HEK 293 (embryonic kidney), HeLa (cervical carcinoma), HepG2 (hepatocellular carcinoma), HL- 60(TB) (leukemia), HOP-62 (non-small cell lung), HOP-92 (non-small cell lung), HS 578T (breast), HT-29 (colon adenocarcinoma), IGR-OV1 (ovarian), IMR32 (neuroblastoma), Jurkat (T lymphocyte), K-562 (leukemia), KM12 (colon), KM20L2 (colon), LAN5 (neuroblastoma), LNCap.FGC (Caucasian prostate adenocarcinoma), LOX IMVI (melanoma), LXFL 529 (non-small cell lung), M14 (melanoma), M19-MEL (melanoma), MALME-3M (melanoma), MCFlOA (mammary epithelial), MCF7 (mammary), MDA-MB- 453 (mammary epithelial), MDA-MB-468 (breast), MDA-MB-231 (breast), MDA-N (breast), MOLT-4 (leukemia), NCI / ADR-RES (ovarian), NCI-H226 (non-small cell lung), NCI-H23 (non-small cell lung), NCI-H322M (non-small cell lung ), NCI-H460 (non-small cell lung),NCI-H522 (non-small cell lung), OVCAR-3 (ovarian), OVCAR-4 (ovarian), OVCAR-5 (ovarian), OVCAR-8 (ovarian), P388 (leukemia), P388 / ADR (leukemia), PC-3 (prostate), PERC6® (E1-transformed embryonal retina), RPMI-7951 (melanoma), RPMI-8226 (leukemia), RXF 393 (renal), RXF-631 (renal), Saos-2 (bone), SF-268 (CNS), SF-295 (CNS), SF-539 (CNS), SHP-77 (small cell lung), SH-SY5Y (neuroblastoma), SK-BR3 (breast), SK- MEL-2 (melanoma), SK-MEL-5 (melanoma), SK-MEL-28 (melanoma), SK-OV-3 (ovarian), SN12K1 (renal), SN12C (renal), SNB-19 (CNS), SNB-75 (CNS) SNB-78 (CNS), SR (leukemia), SW-620 (colon), T-47D (breast), THP-1 (monocyte-derived macrophages), TK- 10 (renal), U87 (glioblastoma), U293 (kidney), U251 (CNS), UACC-257 (melanoma), UACC-62 (melanoma), UO-31 (renal), W138 (lung), and XF 498 (CNS).

[0085] Examples of rodent cell lines useful in methods provided herein include, but are not limited to, baby hamster kidney (BHK) cells (e.g., BHK21 cells, BHK TK− cells), mouse Sertoli (TM4) cells, buffalo rat liver (BRL 3A) cells, mouse mammary tumor (MMT) cells, rat hepatoma (HTC) cells, mouse myeloma (NS0) cells, murine hybridoma (Sp2 / 0) cells, mouse thymoma (EL4) cells, Chinese Hamster Ovary (CHO) cells and CHO cell derivatives, murine embryonic (NIH / 3T3, 3T3 Ll) cells, rat myocardial (H9c2) cells, mouse myoblast (C2C12) cells, and mouse kidney (miMCD-3) cells.

[0086] Examples of non-human primate cell lines useful in methods provided herein include, but are not limited to, monkey kidney (CVI-76) cells, African green monkey kidney (VERO-76) cells, green monkey fibroblast (Cos-1) cells, and monkey kidney (CVI) cells transformed by SV40 (Cos-7). Additional mammalian cell lines are known to those of ordinary skill in the art and are catalogued at the American Type Culture Collection catalog (ATCC®, Mamassas, VA).

[0087] In some embodiments of the methods herein, the cells are lysed using chemical and / or mechanical lysis. In some embodiments, the chemical lysis comprises a lysis buffer comprising a protease inhibitor, phosphate buffered saline and Triton X100. In some embodiments, the cells can be frozen after the addition of the lysis buffer at -80◦C for about 30 minutes to about 72 hours. Alternatively, the cell lysate may be stored in a range of 2 to 8°C or at room temperature. In some embodiments, the cells are centrifuged, and cell lysates are collected. In some embodiments, this is performed by spinning the cells in a centrifuge at 3,750 RPM for 10 minutes at room temperature.

[0088] The methods described herein can be performed by utilizing any of a wide range cell assay formats, including, but not limited to cell plates, e.g., 24-well plates, 48-well plates,96-well plates, or 384-well plates, individual cell culture plates, or flasks, for example T- flasks or shaker flasks.

[0089] The covalent binding of compounds can be detected by assays such as, but not limited to gel assay, NanoBRET assay, western blot, ELISA or microarray. For example, gel assays can include microfluidics or capillary technologies to separate proteins by size.

[0090] In some embodiments, the covalent binding is detected by gel assay. The “gel assays” is defined as an assay in which cells or cell lysates are first treated with a compound for a length of time of 2 minutes-120 hours using techniques known to one skill in the art including but not limited common cell culture techniques. The cells are then lysed using techniques known to one skill in the art including but not limited to sonication or buffer lysis. The resulting lysate, also described as unclarified lysate, of the cells can be further prepared to yield a clarified lysate by using techniques known to one skill in the art including but not limited to centrifugation. The clarified or unclarified lysate likely contains protein that is covalently bound to the molecule of interest or molecules of interest. “Coupling reagents” and a labeling molecule are added to the clarified or unclarified lysate to covalently label the probe compounds in the reaction mixture with a labeling molecule through a copper-free or copper-driven click chemistry reaction. Compound that binds to labeling molecule is then added which enables reliable resolution of stoichiometry and reliable covalent drug tracking. The sample is then run via a western blot method familiar to one skilled in the art. Subsequently, the amount of covalent binding can be tracking based on the shift of the drug treated band compared to the untreated band. The bands can be quantified using densitometry and relative abundances of the bands can be used to determine the quantitative amount of covalent labeling.

[0091] Generally, covalent linking of a large molecular weight protein / mass to a probe compound that leads to a shift of the protein mass complex in a gel can be used. If an azide- linked molecule connected to a high molecular weight protein or molecule of any kind is directly linked to the alkyne on the probe compound, a shift will still occur, and it is possible to detect the covalent binding of the probe to the target, such as PI3K.

[0092] In some embodiments, the covalent binding is detected by gel only shift assay. The “gel only shift assay” is defined as an assay in which a protein is expressed (via transfection or infection) in any cell type and is linked to a tagging domain. This tagging domain includes fluorescent protein or linker protein. The fluorescent proteins include GFP, RFP, etc. This linker proteins include HALO, SNAP-, CLIP-, ACP- and MCP-tags. After transfection or infection, the cells are then treated with a therapeutic conjugate of the present disclosure,wherein the therapeutic conjugate contains an alkyne that can potentially bind covalently. Then, the cells are lysed. In the case of expression of a protein with a linker protein, “coupling reagents” are various probe compounds then added to covalently link a fluorescent dye to the protein of interest. The lysates can then be run on a gel and the target protein visualized via in-gel fluorescence without the need for a western blot transfer. The amount of covalent binding can be tracked based on the shift of the drug treated band compared to the untreated band. The bands can be quantified using densitometry and relative abundances of the bands can be used to determine the quantitative amount of covalent labeling.

[0093] The tagging domain can be any domain which allows for labeling of the target. In some embodiments, the tagging domain includes a label. This label can be included in the domain itself such as an epitope recognized by an antibody or a light detectable or radioactive label. In some embodiments, the label is selected from the group consisting of fluorescent markers, such as such as FITC, phycobiliproteins, such as R- or B-phycoerythrin, allophycocyanin, AlexaFluor dyes, Cy3, Cy5, Cy7, a luminescent marker, a radioactive label such as125I or32P, an enzyme such as horseradish peroxidase, or alkaline phosphatase e.g. alkaline shrimp phosphatase, an epitope, a lectin or biotin / streptavidin.

[0094] The term "secondary label" as used herein refers to moieties such as biotin and various protein antigens that require the presence of a second intermediate for production of a detectable signal. For biotin, the secondary intermediate may include streptavidin-enzyme conjugates. For antigen labels, secondary intermediates may include antibody-enzyme conjugates. Some fluorescent groups act as secondary labels because they transfer energy to another group in the process of nonradiative fluorescent resonance energy transfer (FRET), and the second group produces the detected signal.

[0095]

[0506] The terms "fluorescent label", "fluorescent dye", and "fluorophore" as used herein refer to moieties that absorb light energy at a defined excitation wavelength and emit light energy at a different wavelength. Examples of fluorescent labels include, but are not limited to: Alexa Fluor dyes (Alexa Fluor 350, Alexa Fluor 488, Alexa Fluor 532, Alexa Fluor 546, Alexa Fluor 568, Alexa Fluor 594, Alexa Fluor 633, Alexa Fluor 660 and Alexa Fluor 680), AMCA, AMCA-S, BODIPY dyes (BODIPY FL, BODIPY R6G, BODIPY TMR, BODIPY TR, BODIPY 493 / 503, BODIPY 530 / 550, BODIPY 558 / 568, BODIPY 564 / 570, BODIPY 576 / 589, BODIPY 581 / 591, BODIPY 630 / 650, BODIPY 650 / 665), Carboxyrhodamine 6G, carboxy-X-rhodamine (ROX), Cascade Blue, Cascade Yellow, Coumarin 343, Cyanine dyes (Cy3, Cy5, Cy3.5, Cy5.5), Dansyl, Dapoxyl, Dialkylaminocoumarin, 4',5'-Dichloro-2',7'-dimethoxy-fluorescein, DM- NERF, Eosin,Erythrosin, Fluorescein, FAM, Hydroxycoumarin, IRDyes (IRD40, IRD 700, IRD 800), JOE, Lissamine rhodamine B, Marina Blue, Methoxycoumarin, Naphthofluorescein, Oregon Green 488, Oregon Green 500, Oregon Green 514, Pacific Blue, PyMPO, Pyrene, Rhodamine B, Rhodamine 6G, Rhodamine Green, Rhodamine Red, Rhodol Green, 2',4',5',7'- Tetra- bromosulfone-fluorescein, Tetramethyl-rhodamine (TMR), Carboxytetramethylrhodamine (TAMRA), Texas Red, Texas Red-X, 5(6)-Carboxyfluorescein, 2,7-Dichlorofluorescein, N,N-Bis(2,4,6-trimethylphenyl)-3,4:9,10-perylenebis(dicarboximide, HPTS, Ethyl Eosin, DY-490XL MegaStokes, DY-485XL MegaStokes, Adirondack Green 520, ATTO 465, ATTO 488, ATTO 495, YOYO-l,5-FAM, BCECF, dichlorofluorescein, rhodamine 110, rhodamine 123, YO-PRO-1, SYTOX Green, Sodium Green, SYBR Green I, Alexa Fluor 500, FITC, Fluo-3, Fluo-4, fluoro-emerald, YoYo-1 ssDNA, YoYo-1 dsDNA, YoYo-1, SYTO RNASelect, Diversa Green-FP, Dragon Green, EvaGreen, Surf Green EX, Spectrum Green, NeuroTrace 500525, NBD-X, MitoTracker Green FM, LysoTracker Green DND-26, CBQCA, PA-GFP (post-activation), WEGFP (post-activation), F1ASH-CCXXCC, Azami Green monomeric, Azami Green, green fluorescent protein (GFP), EGFP (Campbell Tsien 2003), EGFP (Patterson 2001), Kaede Green, 7-Benzylamino-4-Nitrobenz-2-Oxa-l,3- Diazole, Bexl, Doxorubicin, Lumio Green, and SuperGlo GFP.

[0096] In some embodiments, a ‘fluorescent protein’ as used herein is, but not limited to Aequorea victoria green fluorescent protein (GFP), Red fluorescent protein (RFP), structural variants of GFP (i.e., circular permutants, monomeric versions), folding variants of GFP (i.e., more soluble versions, superfolder versions), spectral variants of GFP (i.e., YFP, CFP), and GFP like fluorescent proteins (i.e., Dsked). The term “GFP-like fluorescent protein' is used to refer to members of the Antho Zoa fluorescent proteins sharing the 11-beta strand “barrel structure of GFP as well as structural, folding and spectral variants thereof. The terms “GFP- like non-fluorescent protein’ and “GFP-like chromophoric protein’ (or, simply, "chromophoric protein’ or "chromoprotein') are used to refer to the Anthozoa and Hydrozoa chromophoric proteins sharing the 11-beta strand “barrel structure of GFP, as well as structural, folding and spectral variants thereof.

[0097] In some embodiments, the covalent binding is detected by Western blot-based shift assay. The “Western blot-based shift assay” is defined as an assay in which the sample is run via a western blot method familiar to one skilled in the art. Subsequently, the amount of covalent binding can be tracked based on the shift of the target as the covalently bound protein will shift as compared to the non-covalently bound band. The bands can be quantifiedusing densitometry and relative abundances of the bands can be used to determine the quantitative amount of covalent labeling.

[0098] In some embodiments, the covalent binding is detected by ELISA assay. In some embodiments, the covalent binding is detected by ELISA assay 1. The “ELISA assay 1” is defined as an assay in which a lysate that contains the biotin-labeled drug is immobilized on a solid support via hybridization with monomeric or tetrameric streptavidin or a streptavidin variant or a molecule that binds biotin. After the drug is immobilized, a detection antibody is added to detect the drug target of interest. The detection antibody can be covalently linked to an enzyme or can itself be detected by a secondary antibody that is linked to an enzyme or fluorescent label. through bioconjugation. Between each step, the plate is typically washed with a solution to remove any proteins or antibodies that are non-specifically bound. After the final wash step, the plate is developed by adding an enzymatic substrate to produce a visible signal, which indicates the quantity of covalent drug binding to the target of interest. The amount of covalent binding can be track based on the amount of signal.

[0099] In some embodiments, the covalent binding is detected by ELISA assay 2. The “ELISA assay 2” is defined as an assay in which the target of interest is immobilized on a solid support via hybridization with an antibody that binds the target of interest. After the target of interest is immobilized, a detection antibody or monomeric / tetrameric streptavidin or a streptavidin variant is added to detect the drug bound to the target of interest. The detection antibody or monomeric / tetrameric streptavidin or a streptavidin variant can be covalently linked to an enzyme or fluorescent label or can itself be detected by a secondary antibody that is linked to an enzyme or fluorescent label through bioconjugation. Between each step, the plate is typically washed with a solution to remove any proteins or antibodies that are non-specifically bound. After the final wash step, the plate is developed by adding an enzymatic substrate to produce a visible signal or the fluorescent signal is directly measured, which indicates the quantity of covalent drug binding to the target of interest. The amount of covalent binding can be tracked based on the amount of signal.

[0100] In some embodiments, the covalent binding is detected by antibody array. An “antibody array” is defined as a system in which an individual antibody or multiple antibodies are attached to a solid support to enable detection of proteins of interest that bind that antibody and molecules that bind the protein of interest. The antibody microarray consists of a series of individual dots or wells in which a specific antibody has been hybridized to each dot or well (as described in US Patent 20120231963A1, the contents of which are incorporated herein by reference in their entirety). The coupled clarified orunclarified lysate is added to an “antibody microarray” to enable separation of different proteins, localization of specific proteins to their antibody binding partners, or washing away of additional protein. The labeled molecule of interest is detected at each microarray dot or well to examine the amount of covalent binding of the molecule of interest to a specific protein or multiple proteins by detecting the presence of the biotin labeling molecule to reveal a labeling level. The labeling level at each dot will indicate the amount of covalent labeling of the specific protein that has hybridized to the specific antibody. The biotin label on the molecule can be detected via addition of a fluorescent molecule or luminescent enzyme that binds the label including, but not limited to techniques known to one skilled in the art such as fluorescence, luminescence, FRET, or BRET assays. This readout can be detected using approaches known to one skilled in the art including but not limited to fluorescence or luminescence detections schemes.

[0101] In some embodiments, the lysate is labeled with biotin to generate biotinylated compounds. In some embodiments, streptavidin is added to bind to the biotinylated compound. In some embodiments, the streptavidin is monomeric. In some embodiments, the biotinylated compounds are generated by Click chemistry. In some embodiments, the compounds are labeled with click chemistry after the treatment with the probe compound, isolation of cells and cell lysis. In some embodiments, the Click chemistry reagent comprises picolyl azide.

[0102] The term "click chemistry," as used herein, refers to the Huisgen cycloaddition or the 2,3- dipolar cycloaddition between an azide and a terminal alkyne to form a 1,2,4-triazole. The term "cycloaddition" as used herein refers to a chemical reaction in which two or more π- electron systems (e.g., unsaturated molecules or unsaturated parts of the same molecule) combine to form a cyclic product in which there is a net reduction of the bond multiplicity. In a cycloaddition, the π electrons are used to form new sigma bonds. The product of a cycloaddition is called an "adduct" or "cycloadduct". Different types of cycloadditions are known in the art including, but not limited to, [3+2] cycloadditions and Diels-Alder reactions. [3+2] cycloadditions, which are also called 2,3-dipolar cycloadditions, occur between a 1,3- dipole and a dipolarophile and are typically used for the construction of five-membered heterocyclic rings. The terms "[3+2] cycloaddition" also encompasses "copperless" [3+2] cycloadditions between azides and cyclooctynes and difluorocyclooctynes described by Bertozzi et al. J. Am. Chem. Soc., 2004, 126:15046-15047. Any reagent that can be used to facilitate the Huisgen cycloaddition can be used as click chemistry reagent. In some embodiments, detectable moieties are attached to a provided compound via click chemistry.In some embodiments, such moieties are attached via a 1,3-cycloaddition of an azide with an alkyne, optionally in the presence of a copper catalyst. Methods of using click chemistry are known in the art and include those described by Rostovtsev et ah, Angew. Chem. Int. Ed. 2002, 41, 2596-99 and Sun et al, Bioconjugate Chem., 2006, 17, 52-57. In some embodiments, the click chemistry reagent comprises pyridyl azide. In some embodiments, the click chemistry reagent comprises picolyl azide. Without limitation, any isomer of picolyl azide can be used.

[0103] In some embodiments, the probe compound may be associated with or bound to one or more radioactive agents or detectable agents. These agents include various organic small molecules, inorganic compounds, nanoparticles, enzymes or enzyme substrates, fluorescent materials, luminescent materials (e.g., luminol), bioluminescent materials (e.g., luciferase, luciferin, and aequorin), chemiluminescent materials, radioactive materials (e.g.,18F,67Ga,81mKr,82Rb,111In,123I,133Xe,201Tl,125I,35S,14C,3H, or99mTc (e.g., as pertechnetate (technetate(VII), TcO4-)), and contrast agents (e.g., gold (e.g., gold nanoparticles), gadolinium (e.g., chelated Gd), iron oxides (e.g., superparamagnetic iron oxide (SPIO), monocrystalline iron oxide nanoparticles (MIONs), and ultrasmall superparamagnetic iron oxide (USPIO)), manganese chelates (e.g., Mn-DPDP), barium sulfate, iodinated contrast media (iohexol), microbubbles, or perfluorocarbons). Such optically-detectable labels include for example, without limitation, 4-acetamido-4’-isothiocyanatostilbene-2,2′disulfonic acid; acridine and derivatives (e.g., acridine and acridine isothiocyanate); 5-(2′- aminoethyl)aminonaphthalene-1-sulfonic acid (EDANS); 4-amino-N-[3- vinylsulfonyl)phenyl]naphthalimide-3,5 disulfonate; N-(4-anilino-l-naphthyl)maleimide; anthranilamide; BODIPY; Brilliant Yellow; coumarin and derivatives (e.g., coumarin, 7- amino-4-methylcoumarin (AMC, Coumarin 120), and 7-amino-4-trifluoromethylcoumarin (Coumarin 151)); cyanine dyes; cyanosine; 4’,6-diaminidino-2-phenylindole (DAPI); 5′ 5"- dibromopyrogallol-sulfonaphthalein (Bromopyrogallol Red); 7-diethylamino-3-(4’- isothiocyanatophenyl)-4-methylcoumarin; diethylenetriamine pentaacetate; 4,4’- diisothiocyanatodihydro-stilbene-2,2′-disulfonic acid; 4,4’-diisothiocyanatostilbene-2,2′- disulfonic acid; 5-[dimethylamino]-naphthalene-1-sulfonyl chloride (DNS, dansylchloride); 4-dimethylaminophenylazophenyl-4’-isothiocyanate (DABITC); eosin and derivatives (e.g., eosin and eosin isothiocyanate); erythrosin and derivatives (e.g., erythrosin B and erythrosine isothiocyanate); ethidium; fluorescein and derivatives (e.g., 5-carboxyfluorescein (FAM), 5- (4,6-dichlorotriazin-2-yl)aminofluorescein (DTAF), 2′,7’-dimethoxy-4’5′-dichloro-6- carboxyfluorescein, fluorescein, fluorescein isothiocyanate, Xrhodamine- 5-(and-6)-isothiocyanate (QFITC or XRITC), and fluorescamine); 2-[2-[3-[[1,3-dihydro-1,1-dimethyl- 3-(3-sulfopropyl)-2Hbenz[e]indol-2-ylidene]ethylidene]-2-[4-(ethoxycarbonyl)-1- piperazinyl]-1-cyclopenten-1-yl]ethenyl]-1,1-dimethyl-3-(3-sulforpropyl)- 1Hbenz[e]indolium hydroxide, inner salt, compound with N,N-diethylethanamine(1:1) (IR144); 5-chloro-2-[2-[3-[(5-chloro-3-ethyl-2(3H)-benzothiazol- ylidene)ethylidene]-2- (diphenylamino)-1-cyclopenten-1-yl]ethenyl]-3-ethyl benzothiazolium perchlorate (IR140); Malachite Green isothiocyanate; 4-methylumbelliferone orthocresolphthalein; nitrotyrosine; pararosaniline; Phenol Red; B-phycoerythrin; ophthaldialdehyde; pyrene and derivatives(e.g., pyrene, pyrene butyrate, and succinimidyl 1-pyrene); butyrate quantum dots; Reactive Red 4(CIBACRONTM Brilliant Red 3B-A); rhodamine and derivatives (e.g., 6-carboxy-X- rhodamine (ROX), 6-carboxyrhodamine (R6G), lissamine rhodamine B sulfonyl chloride rhodamine (Rhod), rhodamine B, rhodamine 123, rhodamine X isothiocyanate, sulforhodamine B, sulforhodamine 101, sulfonyl chloride derivative of sulforhodamine 101 (Texas Red), N,N,N’,N’tetramethyl-6-carboxyrhodamine (TAMRA) tetramethyl rhodamine, and tetramethyl rhodamine isothiocyanate (TRITC)); riboflavin; rosolic acid; terbium chelate derivatives; Cyanine-3 (Cy3); Cyanine-5 (Cy5); cyanine-5.5 (Cy5.5), Cyanine-7 (Cy7); IRD 700; IRD 800; Alexa 647; La Jolta Blue; phthalo cyanine; and naphthalol cyanine.

[0104] In some embodiments, the detectable agent may be a non-detectable precursor that becomes detectable upon activation (e.g., fluorogenic tetrazine-fluorophore constructs (e.g., tetrazine-BODIPY FL, tetrazine-Oregon Green 488, or tetrazine-BODIPY TMR-X) or enzyme activatable fluorogenic agents (e.g., PROSENSE® (VisEn Medical))).

[0105] As used herein, the terms "occupancy" or "occupy" refer to the extent to which a kinase is modified or bound to by a provided covalent inhibitor compound. One of ordinary skill in the art would appreciate that it is desirable to administer the lowest dose possible to achieve the desired efficacious occupancy of the kinase. In a specific embodiment, the methods and assays may be used for quantifying or determining the occupancy of a target molecule by inhibitors, in particular irreversible inhibitors. See for example, M. T. Labenski et al., Biochemistry 2021, 60, 39, 2915–2924, which is incorporated by reference in its entirety, herein. In the embodiments herein, the target molecule may be PI3K and specifically, PI3Kα.

[0106] In a specific embodiment, the occupancy or percent bound of PI3K or PI3Kα to a target covalent compound can be determined by the following formula:

[0107] The assays of methods of the present invention thus include an assay for binding to and / or occupying the kinase PI3K. In a specific embodiment, a suspected target PI3K irreversible inhibitor can be administered or incubated to cells or a cell lysate thereof that includes the target, PI3K. The PI3K irreversible inhibitor can thus be applied to a cell lysate for example, and irreversibly bind to the population of PI3K from, for example, the cell lysate, cells, tissues, and cells such as B cells or peripheral blood mononuclear cells (PBMCs). The target PI3K irreversible inhibitor can then bind to the protein PI3K wherein a percentage of PI3K is bound by the PI3K irreversible inhibitor. A probe compound bound to a label, for example biotin, can later be applied to the cells or lysate thereof with a percentage of PI3K bound by the PI3K irreversible inhibitor. In a specific embodiment, the target PI3K irreversible inhibitor is applied to pre-lysed cells, thereby determining the drugability or potential of the inhibitor to enter the cell and bind to PI3K. In another embodiment, the cells are then lysed after the addition of the target PI3K irreversible inhibitor, and then the probe compound is added to the lysed cells. The probe compound may then bind to the remaining unoccupied PI3K (i.e., not bound to the PI3K irreversible inhibitor), or at least a percentage of the unoccupied PI3K. Streptavidin may then be additionally added to bind to the biotin labelled probe in the present invention, thereby increasing the mass of the biotin labelled probe that is bound to PI3K or specifically PI3Kα.

[0108] The cells or cell lysates in the present assays may then be treated for gel electrophoresis wherein the PI3K (not bound to the labelled probe bound to streptavidin) is separated from the PI3K bound to the labelled probe bound to streptavidin. A Western analysis can then be performed using a selective anti-PI3K antibody to detect the two separated PI3K bands. Detection of the anti-PI3K antibody and thus quantification of each band (bound or unbound PI3K to the probe) may be determined. Based on quantification, the amount or percentage of PI3K occupied by the PI3K irreversible inhibitor may be determined. For example, well-resolved peaks from gel electrophoresis may be detected with a PI3K specific antibody that recognizes occupied and unoccupied PI3K. Normalized occupancy is then defined as the area of the PI3K peak (bound with PI3K irreversibleinhibitor, but unbound to probe) peak over the total area of the two peaks (unbound and bound with PI3K irreversible inhibitor).

[0109] In a specific embodiment, the target PI3K inhibitor is selected from the group consisting of Compound 1-101 to Compound 1-172 disclosed herein. In another specific embodiment, the target PI3K inhibitor is Compound 1-102. In another specific embodiment, the probe compound is covalently bound to a linker, and the linker (L) is bound to a label (Z) used for detection. In a specific embodiment, the probe compound is a compound from Formula I. In another embodiment, the compound of Formula I is covalently bound to a linker (L), a label (Z), or a linker that is then also bound to a label (Z). In a specific embodiment, the label Z is biotin or a modified biotin.

[0110] In a specific embodiment, the methods may include detecting and / or determining the amount of binding of a target PI3K inhibitor to PI3K in cells or a cell lysate thereof, comprising incubating the target PI3K inhibitor with the PI3K; adding a biotinylated probe compound to PI3K; adding streptavidin or avidin to specifically bind to the biotin, thereby creating an increase in mass to the PI3K bound to the probe, but not to the PI3K bound to the target PI3K inhibitor; running gel electrophoresis and detecting the probe with Western blot of the incubated cell lysate utilizing an anti-PI3K antibody, and determining the amount of target modified by the probe compound by detecting the probe, such as by determining the bands or peaks.

[0111] In a specific embodiment, the methods may include detecting and / or determining the amount of binding or occupancy of a target PI3K inhibitor to PI3K in cells, comprising incubating the target PI3K inhibitor with the PI3K in pre-lysed cells; then lysing the cells before addition of a biotinylated probe compound; adding a biotinylated probe compound to PI3K; adding streptavidin or avidin to specifically bind to the biotin, thereby creating an increase in mass to the PI3K bound to the probe, but not to the PI3K bound to the target PI3K inhibitor; running gel electrophoresis and detecting the probe with Western blot of the incubated cell lysate utilizing an anti-PI3K antibody, and determining the amount of target occupied or modified by the probe compound by detecting the probe.

[0112] In another embodiment, the assay can be used to determine the appropriate dose of a target PI3K inhibitor to a patient. Specifically, by determining the occupancy of the target PI3K inhibitor to the PI3K target in pre-lysed cells, such as the use of whole blood, or PBMCs from whole blood, an approximate maximum clinical dose can be determined for administering to a subject. In a specific embodiment, the maximum tolerated dose in aclinical setting can be estimated or determined by identifying the occupancy of the target PI3K inhibitor in the assays described herein.

[0113] In another embodiment, the methods and assays described herein can be utilized to determine the stability and / or degradation of a target PI3K inhibitor bound to PI3K. In a specific embodiment, the target PI3K inhibitor is administered to a cell line comprising PI3K. After washing any free PI3K inhibitor, the PI3K inhibitor bound to PI3K and the probe compound could be added at different lengths of time post-wash. Streptavidin can then be added to increase mass, followed by gel electrophoresis and Western blot. Occupancy rate can then be determined for each time point post-wash wherein a change in occupancy over time indicates degradation of PI3K inhibitor bound to PI3K over time. In a specific embodiment, the target PI3K inhibitor is compound 1-102 and the probe compound is compound A.

[0114] Accordingly, in a specific embodiment, the methods or assays of the present invention may determine the occupancy PI3K by a PI3K irreversible inhibitor or specific drug characteristics, including the in-cell binding in various cell types to PI3K. In another specific embodiment, the PI3K is PI3Kα.

[0115] In another specific embodiment, the methods and assays of the present invention may be used for detecting and / or determining the amount of binding of a target PI3K inhibitor to PI3K, comprising incubating the target PI3K inhibitor with the PI3K, adding a probe compound to PI3K, and determining the amount of target modified by the probe.

[0116] In another specific embodiment, the method determines the pharmacodynamics of the target PI3K inhibitor and / or the probe compound. In a specific embodiment, the pharmacodynamics of the target PI3K irreversible inhibitor is determined by incubating the target PI3K irreversible inhibitor with the PI3K, adding the probe compound to PI3K, and determining the amount of target modified by the probe compound or measuring the activity of the detectable moiety of the probe compound. The detection can be done by detecting the probe compound at different time points following the administration of the target PI3K inhibitor. For example, the probe compound can include for example a biotinylated label. The biotin label can be further be detected by various means, including a streptavidin antibody. In a specific embodiment, the biotin label is added to the probe compound prior to administration of the assay, i.e., before the probe is added to cell or lysate, or before binding to the target, such as PI3K. In another specific embodiment, the biotinylation step is performed after the probe compound is applied to the cells or lysate and the probe compound is bound to the PI3K target.

[0117] In another example, streptavidin can be added to the assay after the addition of the probe compound. As described above, streptavidin is additionally added to bind to the biotin labelled probe, thereby increasing the mass of the biotin labelled probe that is bound to PI3K. The increase in mass is used as means to differentiate unbound PI3K (not bound to a target PI3K inhibitor, i.e., bound to the probe) or bound PI3K (bound to the target PI3K inhibitor), for example by the use of electrophoresis and Western blot.

[0118] Example 2 demonstrates the use of such an assay. In Example 2, Compound 1-102 is used as the target PI3K inhibitor and is added to T-47D cells. The T-47D cells are then lysed. Compounds A, B, C, D, E and C-1, which are all linked by different means to biotin, are each added to a separate T-47D lysate, wherein each lysate comprises the kinase PI3Kα. After compounds A, B, C, D, E and C-1 are each added to a separate cell lysate, streptavidin is added to specially bind to each biotinylated compound, thereby substantially increasing mass of the PI3Kα bound to the probe compound. Each cell lysate can then be run by gel electrophoresis and an anti-PI3Kα antibody can be used to detect PI3Kα bound and unbound to each compound via Western blot, with the bound compound providing a significant shift in mass over the unbound PI3Kα.

[0119] In another specific embodiment, incubating the target PI3K inhibitor with the PI3K includes providing a dose titration of the target PI3K inhibitor.

[0120] The assays and methods described herein may also be performed in various conditions. For example, the assays and methods may be used using intact cells or a lysis thereof. In another example, the methods and assays may be performed in vitro, in situ, ex vivo, or in vivo. Different assay conditions are described in M. T. Labenski et al., Biochemistry 2021, 60, 39, 2915–2924, which is incorporated by reference in its entirety, herein.

[0121] In another embodiment, various cells comprising PI3K may be used. In one embodiment, the one or more cells is a peripheral blood mononuclear cells (PBMCs). In a specific embodiment, the PBMCs are B cells. In another embodiment, the cell line may include cancer cells or cell lines thereof. For example, in one embodiment, the cancer cells may be related to colorectal cancer, gastric cancer, non-small cell lung cancer, human epidermal growth factor receptor 2 (HER2) negative breast cancer, squamous cell carcinoma of the head and neck, urothelial cancer, breast cancer, or select gynecologic cancers (ovarian cancer, cervical cancer, or endometrial cancer). In a specific embodiment, the cells may be from a subject, such as a human subject. In a specific embodiment, the cells may be related to breast cancer and be a specific breast cancer cell line. In a specific embodiment, the breastcancer cells are T-47D cells. In another embodiment, the cells are a cell lysate or a homogenate. Accordingly, in a specific embodiment, the methods may include the lysing of the cells or suspension thereof. In another embodiment, the methods and assays of the present invention may use and / or comprise compounds or probe compounds described herein. IV. Compounds of the Present Invention

[0122] In a specific embodiment, the probe compound may have a structure of Formula I: (FCB)a-(L)b-(CLM)c, wherein a and c are, independently, integers between 1 and 5, b is an integer between 0 and 5, and wherein the FCB moiety comprises a PI3K inhibitor, or a fragment, analog or derivative thereof. In some embodiments, the FCB may compriseThe probe compound may comprise a structure selected from the group consisting of Compound 1-101 to Compound 1-172.

[0123] In some embodiments, the probe compound may have a structure of Formula II:

[0124] Formula II,or a pharmaceutically acceptable salt thereof, wherein L is selected from the group consisting ofwherein either end can be connected to CLM; R1 is selected from the group consisting of and CLM isselected from the group consisting ofThe probe compound may be selected from the group consisting of compounds 1-101, 1-102, 1-103, 1-104, 1-105, 1-106, 1-107, 1-108, 1-109, 1-110, 1-111, 1-112, 1-113, 1-114, 1-115, 1-116, 1-117, 1-118, 1-119, 1-120, 1-121, 1-122, 1-123, 1-124, 1-125, 1-126, 1-127, 1-128, 1-129, 1-130, 1-137, 1-138, 1-145, 1-146, 1-153, 1-154, 1-161, 1-162, 1-169, 1-170, 1-171 and 1-172.

[0125] In some embodiments, the probe compound may have a structure of Formula III: Formula III,or a pharmaceutically acceptable salt thereof, wherein L isR2 is selected from the group consisting of and CLM is selected from thegroup consisting of, , , ,The probe compound may be selected from the group consisting of compounds 1-131, 1-132, 1-133, 1-134, 1-135, 1-136, 1-139, 1-140, 1- 141, 1-142, 1-143, 1-144, 1-147, 1-148, 1-149, 1-150, 1-151, 1-152, 1-155, 1-156, 1-157, 1- 158, 1-159, 1-160, 1-163, 1-164, 1-165, 1-166, 1-167 and 1-168.

[0126] In some embodiments, the probe compound may comprise a structure selected from Compound 1-101 to Compound 1-172, or a pharmaceutical acceptable salt thereof. In some embodiments, the probe compound may comprise a structure selected from Compound 1-1 to Compound 1-11, or a pharmaceutical acceptable salt thereof.

[0127] In some embodiments, the compounds of Formula I are selected from the group consisting of narrow generic structures Compound 1-6 to Compound 1-11,or a pharmaceutically acceptable salt thereof.

[0128] In some embodiments, the probe compound may have a structure of Formula II:Formula II,

[0129] or a pharmaceutically acceptable salt thereof, wherein L is a linker selected from the group consisting ofwherein either end can be connected to the CLM; R1 is selected from the group consisting of, , ; and CLM is selected from the group consisting of. The compounds encompassed by Formula II include but not limited to Compound 1-101, 1- 102, 1-103, 1-104, 1-105, 1-106, 1-107, 1-108, 1-109, 1-110, 1-111, 1-112, 1-113, 1-114, 1- 115, 1-116, 1-117, 1-118, 1-119, 1-120, 1-121, 1-122, 1-123, 1-124, 1-125, 1-126, 1-127, 1- 128, 1-129, 1-130, 1-137, 1-138, 1-145, 1-146, 1-153, 1-154, 1-161, 1-162, 1-169, 1-170, 1- 171 and 1-172 in Table 1 below.

[0130] In some embodiments, the probe compound may have a structure of Formula III:Formula III, or a pharmaceutically acceptable salt thereof, wherein L, the linker is R2 is selected from the group consisting of; and CLM is selected from the group consisting ofThe compounds encompassed by Formula III include but not limited to Compound 1-131, 1-132, 1-133, 1-134, 1-135, 1-136, 1-139, 1-140, 1-141, 1-142, 1-143, 1-144, 1-147, 1-148, 1-149, 1-150, 1-151, 1-152, 1-155, 1-156, 1-157, 1-158, 1-159, 1-160, 1-163, 1-164, 1-165, 1-166, 1-167 and 1-168 in Table 1 below.

[0131] Exemplary probe compounds include any compound selected from the group consisting of Compound 1-101 to Compound 1-172.Table 1. Non-limiting Examples of Probe Compoundsor a pharmaceutically acceptable salt thereof.

[0132] In another specific embodiment, a probe compound of Formula I, II or III, may be further covalently bound to a linker (K) and / or a label (Z). In a specific embodiment, the probe compound is covalently bound to a linker, and the linker (L) is bound to a label (Z) used for detection. In another embodiment, the probe compound is covalently bound to a label (Z) used for detection. In another specific embodiment, a probe compound of Formula I, II or III, may be further covalently bound to a linker (K) and / or a label (Z), wherein one or more atoms or chemical groups on the compound is replaced by a bond to the linker K or the label Z.

[0133] In a specific embodiment, the probe compound may be a compound of Formula (A):wherein: Z is a label; K is a linker; and (FCB)a-(L)b-(CLM)c is a compound of Formula I, II, or III as described above. In a specific embodiment, the probe compound could be Compound 1-102 below or comprise Compound 1-102 below:or pharmaceutically acceptable salt thereof.

[0134] In a specific embodiment, the probe compound may be a compound of Formula (A):wherein: Z is a label; K is a linker; (FCB)a-(L)b-(CLM)c is a compound having the structure:, wherein one or more atoms or chemical groups on the compound is replaced by a bond to the linker K.

[0135] In another embodiment, the probe compound is a compound of Formula (B)Formula (B), or a pharmaceutically acceptable salt thereof.

[0136] In embodiments, the compound of Formula (B) is a compound of Formula (C):Formula (C), or a pharmaceutically acceptable salt thereof.

[0137] In embodiments, provided herein is a probe compound of Formula (I):wherein: Z is a label; K is a linker; (FCB)a-(L)b-(CLM)c is a compound of Formula (I):or a pharmaceutically acceptable salt thereof, wherein one or more atoms or chemical groups on the compound of Formula I is replaced by a bond to the linker K; andwherein L is selected from the group consisting of:R1 is selected from the group consisting of:CLM is selected from the group consisting of :, , , , or a pharmaceutically acceptablesalt thereof.

[0138] In some embodiments, suitable linking positions on the (FCB)a-(L)b-(CLM)c compound allow binding of the (FCB)a-(L)b-(CLM)c compound to the PI3 kinase. In some embodiments, suitable linking positions on the (FCB)a-(L)b-(CLM)c compound provide maximum binding of the (FCB)a-(L)b-(CLM)c compound to the PI3 kinase. In one embodiment, any of the linkers K disclosed herein can be the linker as covalently attached to the Z and / or to the probe compound. In certain embodiments, any of the linkers K disclosed herein can describe the linker moiety before covalently attaching it to the probe compound and / or to the label Z. In a non-limited example, linker K can comprise a chemical group (e.g., alcohol, amine, azides, -C≡CH, etc) which can be reacted with another chemical group on or attached to the label Z and / or the probe compound in order to form a covalent bond,e.g., amine bond, ether bond, amide bond, ester bond, triazole (Click chemistry). In one embodiment, a chemical group already present in the K as described herein can be used to covalently attach the K to the label Z and / or to the probe compound. The chemistry used to covalently attach the linker K can be readily understood by one skilled in the art. Unless otherwise expressly stated, the linkers described herein can connect to the rest of the compound in either direction.

[0139] In some embodiments of the compounds of Formula (I), the linker K has the formula: —KXA—Y—KXB— wherein KXA and KXB are each independently, absent (a bond), –(CH2)m1, –O–, – NR10(R10)–, –C(O)–, –C(O)NR10–, –N(R10)–, or –NR10C(O)–; –NR10CH2–, or an optionally substituted aryl ring, heteroaryl ring, carbocycle, or heterocycle; wherein Y is –(CH2)m1–, –(CH2)m1-O–, –(CH2)m2-NR10–, –(CH2)m2-(CH2CH2–W1)m1-, or -(CH2)m1–(CH2CH2–W1)m2-(CH2CH2CH2–W2)m2-(CH2)m1– W3; W1is –O–, –S–, –N(R10)–, –C(O)–, –C(O)NR10–, –NR10C(O)–, or –(CH2)m1–; W2is –C(O)–, –C(O)NR10–, –NR10C(O)–, –(CH2)m1–; W3can be absent or can be an optionally substituted aryl ring, carbocycle, heterocycle or heteroaryl ring; each R10is independently hydrogen, C1-C3alkyl, or C1-C3haloalkyl; each m1 is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12; and each m2 is independently 0, 1, 2, 3, 4, 5, or 6.

[0140] In a specific, the linker K comprises polyethylene glycol (PEG). In some embodiments the linker K is or comprises a polyethylene glycol chain ranging in size from about 1 to about 12 ethylene glycol units, wherein each –CH2– in the polyethylene glycol is optionally substituted. In some embodiments, the linker K is or comprises a polyethylene glycol chain ranging in size from about 2 to about 10 ethylene glycol units, wherein each – CH2– in the polyethylene glycol is optionally substituted. In some embodiments, the linker K is or comprises a polyethylene glycol chain ranging in size from about 3 to about 5 ethylene glycol units, wherein each –CH2– in the polyethylene glycol is optionally substituted. In a specific embodiment, W1is –O–.

[0141] In another specific embodiment, a label may be attached or covalently linked to the compounds of Formula I. In a specific embodiment, the label (Z) is biotin or a modifiedbiotin. In another embodiment, the label may be detected by various means, including the binding of other compounds to increase mass of the label and probe compound. In a specific embodiment, the label can be detected by an antibody. In another embodiment, the label Z may include a secondary label that can be detected by fluorescent resonance energy transfer (FRET). In another embodiment, the label may include a florescent label. Examples of fluorescent labels include, but are not limited to: Alexa Fluor dyes (Alexa Fluor 350, Alexa Fluor 488, Alexa Fluor 532, Alexa Fluor 546, Alexa Fluor 568, Alexa Fluor 594, Alexa Fluor 633, Alexa Fluor 660 and Alexa Fluor 680), AMCA, AMCA-S, BODIPY dyes (BODIPY FL, BODIPY R6G, BODIPY TMR, BODIPY TR, BODIPY 493 / 503, BODIPY 530 / 550, BODIPY 558 / 568, BODIPY 564 / 570, BODIPY 576 / 589, BODIPY 581 / 591, BODIPY 630 / 650, BODIPY 650 / 665), Carboxyrhodamine 6G, carboxy-X-rhodamine (ROX), Cascade Blue, Cascade Yellow, Coumarin 343, Cyanine dyes (Cy3, Cy5, Cy3.5, Cy5.5), Dansyl, Dapoxyl, Dialkylaminocoumarin, 4',5'-Dichloro-2',7'-dimethoxy-fluorescein, DM- NERF, Eosin, Erythrosin, Fluorescein, FAM, Hydroxycoumarin, IRDyes (IRD40, IRD 700, IRD 800), JOE, Lissamine rhodamine B, Marina Blue, Methoxycoumarin, Naphthofluorescein, Oregon Green 488, Oregon Green 500, Oregon Green 514, Pacific Blue, PyMPO, Pyrene, Rhodamine B, Rhodamine 6G, Rhodamine Green, Rhodamine Red, Rhodol Green, 2',4',5',7'- Tetra-bromosulfone-fluorescein, Tetramethyl-rhodamine (TMR), Carboxytetramethylrhodamine (TAMRA), Texas Red, Texas Red-X, 5(6)- Carboxyfluorescein, 2,7-Dichlorofluorescein, N,N-Bis(2,4,6-trimethylphenyl)-3,4:9,10- perylenebis(dicarboximide, HPTS, Ethyl Eosin, DY-490XL MegaStokes, DY-485XL MegaStokes, Adirondack Green 520, ATTO 465, ATTO 488, ATTO 495, YOYO-l,5-FAM, BCECF, dichlorofluorescein, rhodamine 110, rhodamine 123, YO-PRO-1, SYTOX Green, Sodium Green, SYBR Green I, Alexa Fluor 500, FITC, Fluo-3, Fluo-4, fluoro-emerald, YoYo-1 ssDNA, YoYo-1 dsDNA, YoYo-1, SYTO RNASelect, Diversa Green-FP, Dragon Green, EvaGreen, Surf Green EX, Spectrum Green, NeuroTrace 500525, NBD-X, MitoTracker Green FM, LysoTracker Green DND-26, CBQCA, PA-GFP (post-activation), WEGFP (post-activation), F1ASH-CCXXCC, Azami Green monomeric, Azami Green, green fluorescent protein (GFP), EGFP (Campbell Tsien 2003), EGFP (Patterson 2001), Kaede Green, 7-Benzylamino-4-Nitrobenz-2-Oxa-l,3-Diazole, Bexl, Doxorubicin, Lumio Green, and SuperGlo GFP.

[0142] In a specific embodiment, the label is biotin. In a specific embodiment, the probe compounds may include any compound from Formula (I), (II), (III), (A) or (B), wherein the label is biotin. In a specific embodiment, Z is biotin and linked to Formula (I), (II), (III), (A)or (B), by various methods known in the art, including click chemistry. In a specific embodiment, Formula I can be one of the following compounds:(Compound C);(Compound E). In a specific embodiment, and the assays described herein, the compounds or assays can be tested or compared to compound C-1, below:ĨCompound C-1).

[0143] In a specific embodiment, the linkers can be linked by the use of an amide bond or the use of a triazole, i.e., click chemistry. In a specific embodiment, the label, and thus the probe compound bound to the label, may be detected by binding to avidin, streptavidin, neutravidin, or captavidin.

[0144] In another specific embodiment, the label and thus the probe compound is detected by various methods including one of more of the group consisting of Western blot, ELISA, flow cytometry, and mass spectrometry, including LC-MS, and LC-MS-MS. In another embodiment, the methods or assays herein include detecting and / or determining the amount of binding of a target PI3K inhibitor to PI3K in cells or a cell lysate thereof, comprising incubating the target PI3K inhibitor with the PI3K, adding a biotinylated probe compound to PI3K, running gel electrophoresis and detecting the probe with Western blot of the incubated cell lysate utilizing an avidin labelled antibody, and determining the amount of target modified by the probe compound by detecting the probe. In another specific embodiment, the pharmacodynamics of the target PI3K irreversible inhibitor is determined by incubating the target PI3K irreversible inhibitor with the PI3K, adding the biotinylated probe compound to PI3K, and determining the amount of target modified by the probe compound or measuring the activity of the detectable moiety of the probe compound by detecting the probe compound at different time points following the administration of the target PI3K inhibitor.

[0145] It will be appreciated that the following examples are intended to illustrate but not to limit the present disclosure. Various other examples and modifications of the foregoing description and examples will be apparent to a person skilled in the art after reading the disclosure without departing from the spirit and scope of the disclosure, and it is intended that all such examples or modifications be included within the scope of the appended claims. All publications and patents referenced herein are hereby incorporated by reference in their entirety. EXAMPLES

[0146] Example 1: Evaluation of Biotin-probes Using T-47D Lysates

[0147] T-47D cells are lysed using lysis buffer [150 mM NaCl, 20 mM Tris (pH 7.5), and 1% Triton X-100] complete with 1× protease and phosphatase inhibitor cocktails. Cellular debris is cleared by centrifugation (>13000g, 4 °C, 10 min), and the supernatant is collected. The protein concentration is determined using Pierce 660 nm Protein Assay Reagent and normalized to 0.75 mg / mL. T-47D cell lysate samples are treated with biotinylated covalent probes for 2 hrs. Each sample is then mixed 1:1 with a 1 mg / mL streptavidin solution and incubated for 10 min. The samples are then prepared for loading on gel electrophoresis and Western blot analysis is performed with a primary antibody specific to PI3Kα.

[0148] Example 2: Evaluation of Biotin-probes Using T-47D Lysates

[0149] Compound 1-102 was added to multiple batches of pre-lysed T-47D cells for 2hrs at room temperature at a range of 1000 nM to 5 nM. After the 2 hr incubation, teach batch of T-47D cells was lysed, and compounds A, B, C, D, E and C1 were each added to separate T- 47D lysate samples each at a concentration of 5 µM for 30 min. After compounds A, B, C, D, E and C1 are each added to a separate cell lysate, streptavidin is added. Each cell lysate was then run by gel electrophoresis and an anti-PI3Kα antibody for Western blot analysis was used to detect PI3Kα bound and unbound to each probe compound, with the probe compound bound providing a significant shift in mass over the unbound PI3Kα. Results are shown in Fig.1, with a lysate example with no addition of each compound, and the addition of each compound A, B, C, D, E and C1. The lanes with the additions A, B, C, D, E and C1 shows a band with an increased mass, demonstrating that for Compound A and C1, a significant amount of PI3Kα is bound or occupied to the compound A probe or C1 probes. In contrast, a lesser amount of PI3Kα is bound to or occupied by probe Compounds B, C, D, and E with a detected portion of PI3Kα also remaining unbound.

[0150] Example 3: Dose-dependent Correlation of Occupancy of PI3Kα and Pathway Inhibition in T-47D Cells

[0151] Compound 1-102 was diluted at various concentrations between 0.07 µM to 50 µM and was added to separate T-47D cell samples for 2 hrs. After addition of Compound 1-102, the T-47D cells were lysed and the biotinylated probe compound A was added to the cell lysate at a concentration of 5 µM for 30 min. Streptavidin is then added to the cell lysate. Electrophoresis and Western blot analysis was performed as above in Example 1 indicating the binding of compound-102 to PI3Kα, thereby occupying the kinase and inhibiting the probe compound A from binding to PI3Kα. As indicated in Fig.2, the increasedconcentration of compound 1-102, thereby more compound 1-102 bound to PI3Kα, correlates to an increased lack of binding of the probe compound A to PI3Kα. The binding of compound 1-102 is confirmed as also being active, indicated by the reduction of phosphorylated AKT at the S473 residue position when the concentration of compound 1-202 is increased. Accordingly, compound 1-102 occupancy correlates with the inhibition of PI3K pathway in the T-47D cell line. This is also confirmed in other cancer cell lines. The same assay was performed in T84 carcinoma cells (See Fig.8), again showing compound 1- 102 occupancy correlating to inhibition of the PI3K pathway. Fig.9 shows a correlation of %PI3Kα bound vs %AKT S473 phosphorylation in both cell lines, wherein for T-47D cultured cells, the EC50 occupancy is 23 nM and the EC50 of AKT S473 phosphorylation is 12 nM, and for T84 cultured cells, the EC50 occupancy is 5.2 nM and the EC50 of AKT S473 phosphorylation is 20 nM.

[0152] Example 4: Occupancy by Compound 1-102 in Human PBMCs

[0153] Compound 1-102 was diluted at various concentrations between 0.03 µM to 30 µM and each concentration was added to separate Human PBMC lysate samples. This assay was performed similarly to Example 2 using compound A as the biotinylated probe, but with PBMC cells from 2 different donors. Fig.3 shows that as the concentration of compound 1- 102 is increased, more of PI3Kα is occupied and the binding of the probe to PI3Kα is reduced.

[0154] Example 5: Occupancy of in T-47D cells and PBMCs

[0155] Compound 1-102 was diluted at various concentrations between 5 nM to 1000 µM and was added to separate purified T-47D cell samples or purified PBMC samples. This assay was performed similarly to Example 2 using compound A as the biotinylated probe. Fig.4 shows that as the concentration of compound 1-102 is increased, more of PI3Kα is occupied and the binding of the probe to PI3Kα is reduced in both T-47D cells and PBMCs.

[0156] Indeed, Fig.5 shows the PI3Kα occupancy in PBMCs, indicating these PBMC cells show a concentration dependent % occupancy of PI3Kα with an EC50 for occupancy in PBMCs is 24 nM for compound 1-102.

[0157] Example 6: Occupancy of PI3Kα in PBMCs isolated from Treated Whole Blood

[0158] The use of PBMCs as the source of clinical material was validated using samples of whole blood. In this example, samples of whole blood were “spiked” with different concentrations of compound 1-102 followed by Ficoll gradient isolation of PBMCs, and cell lysis and occupancy assay as performed in Example 2 using compound A as the biotinylated probe. See Fig.6. This experiment reveals a Compound 1-102 concentration dependent % occupancy in PBMCs from whole blood with an EC50 of 129 nM. The difference between the EC50s determined for purified PBMCs and in whole blood is likely due to compound 1- 102 plasma protein binding.

[0159] Example 7: Occupancy Assay shows stability / degradation of Target Compound bound to PI3Kα

[0160] The occupancy assay can be used to explore the PI3Kα protein turnover in cancer cell lines. The degradation of compound 1-102 bound PI3Kα could be monitored over time and would be reflected in a temporal change in % occupancy. The occupancy assay was performed similar to Example 2 above, but with AGS cells or T-47D cells. Furthermore, to determine degradation, compound 1-102 was added to AGS cells or T-47D cells for 12 hrs at a concentration of 1 µM. After 12 hours, the cells were washed at a given washout time and the occupancy assay was run as in Example 2 above using compound A as a probe compound. Specifically, after the given washout time, the cells were lysed, mixed with probe compound A, followed by the addition of streptavidin and then gel electrophoresis and Western blot was performed.

[0161] As shown in Fig.7, these experiments reveal that the turnover of PI3Kα in cancer cells is slow, highlighting durable target occupancy and pathway inhibition achievable by compound 1-102, resulting in superior efficacy observed in multiple cancer models representing varied histologies. EQUIVALENTS AND SCOPE

[0162] Those skilled in the art will recognize or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments in accordance with the disclosure described herein. The scope of the present disclosure is not intended to be limited to the above Description, but rather is as set forth in the appended claims.

[0163] In the claims, articles such as “a,” “an,” and “the” may mean one or more than one unless indicated to the contrary or otherwise evident from the context. Claims or descriptionsthat include “or” between one or more members of a group are considered satisfied if one, more than one, or all of the group members are present in, employed in, or otherwise relevant to a given product or process unless indicated to the contrary or otherwise evident from the context. The disclosure includes embodiments in which exactly one member of the group is present in, employed in, or otherwise relevant to a given product or process. The disclosure includes embodiments in which more than one, or the entire group members are present in, employed in, or otherwise relevant to a given product or process.

[0164] It is also noted that the term “comprising” is intended to be open and permits but does not require the inclusion of additional elements or steps. When the term “comprising” is used herein, the term “consisting of” is thus also encompassed and disclosed.

[0165] Where ranges are given, endpoints are included. Furthermore, it is to be understood that unless otherwise indicated or otherwise evident from the context and understanding of one of ordinary skill in the art, values that are expressed as ranges can assume any specific value or subrange within the stated ranges in different embodiments of the disclosure, to the tenth of the unit of the lower limit of the range, unless the context clearly dictates otherwise.

[0166] In addition, it is to be understood that any particular embodiment of the present disclosure that falls within the prior art may be explicitly excluded from any one or more of the claims. Since such embodiments are deemed to be known to one of ordinary skill in the art, they may be excluded even if the exclusion is not set forth explicitly herein. Any particular embodiment of the compositions of the disclosure (e.g., any antibiotic, therapeutic or active ingredient; any method of production; any method of use; etc.) can be excluded from any one or more claims, for any reason, whether or not related to the existence of prior art.

[0167] It is to be understood that the words which have been used are words of description rather than limitation, and that changes may be made within the purview of the appended claims without departing from the true scope and spirit of the disclosure in its broader aspects.

[0168] While the present disclosure has been described at some length and with some particularity with respect to the several described embodiments, it is not intended that it should be limited to any such particulars or embodiments or any particular embodiment, but it is to be construed with references to the appended claims so as to provide the broadest possible interpretation of such claims in view of the prior art and, therefore, to effectively encompass the intended scope of the disclosure.

Claims

WHAT IS CLAIMED IS:

1. A method for detecting and / or determining the amount of binding of a target PI3K inhibitor to PI3K, comprising incubating or adding the target PI3K inhibitor to the PI3K, adding a probe compound to PI3K, and determining the amount of target modified by the probe compound by detecting the probe.

2. The method of claim 1, wherein the method determines the occupancy of the target PI3K inhibitor to PI3K.

3. The method of claim 1 or claim 2, wherein the method determines the pharmacodynamics of the target PI3K inhibitor and / or the probe compound.

4. The method of claim 2, the occupancy is determined by administering the target PI3K inhibitor in whole blood, whole cells or pre-lysed cell samples.

5. The method of any one of claims 1-4, wherein the incubating the target PI3K inhibitor with the PI3K includes administering a range of different concentrations of target PI3K inhibitor to PI3K, wherein each concentration of target PI3K inhibitor is administered to a separate sample comprising PI3K; determining the occupancy of PI3K for each concentration of target PI3K inhibitor; and determining an EC50 occupancy and / or maximum dose of the target PI3K inhibitor for achieving maximum occupancy of PI3K.

6. The method of any one of claims 1-5, wherein the assay is performed in vitro or in vivo.

7. The method of any one of claims 1-6, wherein the method is presented within one or more cells or a lysate thereof.

8. The method of claim 7, wherein the one or more cells is a peripheral blood mononuclear cells (PBMCs).

9. The method of claim 8, wherein the PBMCs are B cells.

10. The method of claim 7, wherein the one or more cells is breast cancer cells.

11. The method of claim 10, wherein the breast cancer cells are T-47D cells.

12. The method of any one of claims 8-11, wherein the cells are lysates thereof.

13. The method of any one of claims 1-12, wherein the methods include post lysis of the cells, adding compounds that bind to or detect the probe, thereby increasing the mass of the probe bound to the PI3K.

14. The method of claim 13, wherein the PI3K is PI3Kα.

15. The method of any one of claims 1-14, wherein the probe compound is covalently bound to a linker, and the linker (K) is bound to a label (Z) used for detection.

16. The method of any one of claims 1-15, wherein the probe compound is covalently bound to a label (Z) used for detection.

17. The method of any one of claims 1-16, wherein the probe compound is a compound of Formula I, II, III, A, or B.

18. The method of claim 17, wherein the compound of Formula 1 is or comprises the following structure:Compound 1-102.

19. The method of claim 18, wherein the compound of Formula I, is compound is covalently bound to a linker, or a label (Z).

20. The method of any one of claims 17-19, wherein the linker comprises PEG.

21. The method of any one of claim 1-20, wherein the probe compound is detected by one of more of the group consisting of Western blot, ELISA, flow cytometry, and mass spectrometry, including LC-MS, and LC-MS-MS.

22. The method of any one of claims 1-21, wherein the label (Z) is biotin or a modified biotin.

23. The method of any one of claims 1-22, wherein the label (Z) is detected by the administration of avidin, streptavidin, neutravidin, or captavidin, wherein the probe compound bound to label (Z) increases in mass in view of the binding of avidin, streptavidin, neutravidin, or captavidin.

24. A method for detecting and / or determining the amount of binding of a target PI3K inhibitor to PI3K in cells, comprising incubating the target PI3K inhibitor with the PI3K in pre-lysed cells; lysing the cells; adding a biotinylated probe compound to the lysed cells comprising PI3K; adding streptavidin to the lysed cells; running gel electrophoresis of the lysed cell samples and detecting the biotinylated probe compound with Western blot of the incubated cell lysate utilizing an anti-PI3K antibody; and determining the amount of PI3K occupied or unoccupied by the target PI3K inhibitor by detecting PI3K in each band of occupied PI3K or unoccupied PI3K in the Western blot.

25. The method of claim 24, wherein the stability or degradation of the target PI3K inhibitor bound to PI3K is determined by incubating the target PI3K inhibitor with the PI3K, adding the biotinylated probe compound to PI3K, and determining the amount of target modified by the probe compound or measuring the activity of the detectable moiety of the probe compound by detecting the probe compound at different time points following the administration of the target PI3K inhibitor.

26. The method of any one of claims 1-25, wherein the target PI3K inhibitor is compound 1-102.

27. The method of any one of claims 1-26, wherein the probe compound is one or more compounds selected from the group consisting of compounds A-E.

28. A probe compound of Formula I, II or III, further covalently bound to a linker (K) and / or a label (Z).

29. The probe compound of claim 28, wherein the probe compound is a compound of Formula (A):wherein: Z is a label; K is a linker; and (FCB)a-(L)b-(CLM)c is a compound of Formula I, II, or III.

30. The probe compound of claim 28 or 29, wherein the probe compound comprises the following structure:.

31. The probe compound of any one of claims 28-30, wherein the probe compound is a compound of Formula (A):, or a pharmaceutically acceptable salt thereof; (A) wherein: Z is a label; K is a linker;(FCB)a-(L)b-(CLM)c is a compound having the structure:wherein one or more atoms or chemical groups on the compound is replaced by a bond to the linker K.

32. The probe compound of any one of claims 28-31, wherein the probe compound is a compound of Formula (B):Formula (B), or a pharmaceutically acceptable salt thereof.

33. The probe compound of claim 32, wherein the probe compound is a compound of Formula (B) is a compound of Formula (C):Formula (C), or a pharmaceutically acceptable salt thereof.

34. The probe compound of any one of claims 28-33, wherein the probe compound is a compound of Formula wherein:Z is a label;K is a linker; (FCB)a-(L)b-(CLM)c is a compound of Formula (I):or a pharmaceutically acceptable salt thereof, wherein one or more atoms or chemical groups on the compound of Formula I is replaced by a bond to the linker K; and wherein L is selected from the group consisting of:R1is selected from the group consisting of:CLM is selected from the group consisting of :or a pharmaceutically acceptable salt thereof.

Citation Information

Patent Citations

  • Heterocyclylamines as PI3k inhibitors

    US20130059835A1

  • Therapeutic conjugates

    WO2021055747A1

  • Therapeutic conjugates

    WO2022198024A1